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SUMMARY 
 
 
CREB, cAMP responsive element binding protein is a positive regulatory protein 
transcriptional factor, for genes including aromatase, an enzyme that converts androgens 
to oestrogens, c-fos, tyrosine hydroxylase and neuropeptides like somatostatin and 
enkephalin. The expression of aromatase is highly aberrant in human breast cancer and 
has been implicated in the disease progression. Aromatase expression in breast cancer 
tissue is directed mainly by promoters 1.3 and II.  CRE1 and CRE2 are essential for 
cAMP induced promoter II activity. CRE binding protein (CREB) bound to this element 
(CRE) and that this interaction was enhanced in the presence of cAMP. Despite the 
extensive work on aromatase, little information is available on the expression and role of 
CREB in human breast cancer.  
 
The aim of this study was to investigate the molecular impact of CREB family of proteins 
on the aggressive nature of breast cancer cells and to investigate the expression pattern in 
breast cancer tissues in relation to tumour histopathological grade, stage, nodal status and 
the clinical outcome of the patients. 
 
In this study we examined the expression of CREB1 and ATFs (Activating transcription 
factors) in breast cancer cell lines using RT-PCR, which allowed us to design the strategy 
of in vitro experiments. Ribozyme knockdown technology was used to target the 
expression of CREB1 in a breast cancer cell line MDA-MB-231. Knockdown of CREB1 
using ribozyme transgenes resulted in decrease in in vitro cell growth and invasiveness in 
breast cancer cells. The results presented here demonstrate that the level of CREB-1 and 
ATFs in breast cancer patients was elevated. The study results presented here revealed a 
significant link between CREB and mortality, in that high levels are associated with 
shorter disease free survival and interestingly we found significantly low levels of ATFs 
in patients with poor prognosis, metastatic disease and nodal involvement. We conclude 
that the level of CREB-1 and ATFs are aberrantly expressed in human breast cancer 
which may be associated with disease progression in breast cancer patients and has 
significant bearing to the clinical outcome of the patients. 
 
Over-expression of aromatase in adipose tissue surrounding breast tumour could arise 
through increase in both CREB expression and CREB transcriptional activity. Inhibition 
of CREB activity could inhibit aromatase expression and hence decrease oestrogen 
production in breast tissue. An understanding of the molecular mechanisms of expression 
of CREB, together with aromatase between non-cancerous and cancerous breast tissue at 
both transcriptional and translational levels may help in the design of a therapy based on 
suppressing aromatase expression in breast cancer tissues. 
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rpm                  Revolutions per minute 
RT                   Reverse Transcription 
SD                   Standard Deviation 
sec                   Second 
TBE                Tris/ Borate/ EDTA electrophoresis buffer 
U                     Unit 
V                     Volt 
WT                  Wild type 
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1.1 Breast Cancer 
1.1.1 Epidemiology  
Breast Cancer is a major health issue and is the most frequently occurring cancer in 
women worldwide. It accounts for about 25 per cent of all female malignancies and the 
proportion is higher in women in developed countries with incidence rising in many parts 
of the world including Europe and USA. Over one million new cases occurs each year 
worldwide (Parkin et al., 2001). There is substantial geographical variation in age- 
adjusted incidence rates with the highest rates reported in Northern America and Europe 
and the lowest in the Far East (Figure 1.1) which is mostly attributed to the introduction 
of screening programme in these regions. As shown in the graph the survival rate in 
developed countries is much higher as compared to developing countries and hence the 
differences in mortality rates worldwide being much less marked than for incidence 
(Figure 1.2).  
Breast cancer is the most common female cancer in UK accounting for 31% of all cases 
in women (Cancer Research UK 2011). The life time risk of developing breast cancer in 
the UK is 1 in 8, with an estimated 48,000 new cases diagnosed in 2008 (Cancer 
Research UK 2011). Incidence rates of breast cancer in UK have continued their upward 
trend as well, increasing by 80 per cent between 1975 and 2008. (Figure 1.2) (Cancer 
Research UK 2011). Breast cancer is the second most common cause of death from 
cancer accounting for 16% of all cases in women and around 12,000 women died from 
breast cancer in United Kingdom in 2008. Fortunately, the incidence of breast cancer 
appears to have reached a plateau and mortality rates are improving mainly due to more 
effective treatments and earlier detection of cancer by screening.  
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Figure 1.1: Age standardised incidence and Mortality rates of female breast 
cancer in selected world regions, 2008 
(Adapted from Cancer Research UK, 2011) 
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Figure 1.2: Age standardised incidence and mortality rates of female breast 
cancer- United Kingdom (1975-2008) 
(Adapted from Cancer Research UK, 2011) 
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1.1.2 Aetiology of Breast Cancer: Environmental and Genetic Factors 
Female breast cancer is a complex, multifactorial disease, the aetiology of which involves 
a strong association between environmental, genetic and behavioural factors. Several risk 
factors are well established and are shown in Table 1.1. The strongest associated risk 
factor that affects most women is increasing age. Breast cancer is a rare disease in women 
under 35 years old but its incidence double every 5 years until the age of 50 with the peak 
in the 50 to 64 age group (Figure 1.3 & Figure 1.4) (Cancer Research UK, 2011) (Kelsey  
et al., 1988). Eighty per cent of cases occur in post-menopausal women. This cancer 
accounts for almost one in three of all cancer cases in women, and the life time risk for 
breast cancer in women is one in eight. The estimated risk of developing breast cancer for 
different age group is shown in Table 1.2.  
The most important influence is hormonal factors, especially the determinants of 
menstrual life and childbirth history. Women who began having periods early (before 12 
years of age) or who attain menopause after the age of 55 have a slightly increased risk of 
breast cancer. Women who had no children, or who had their first child after age 30, have 
a slightly higher risk of breast cancer (Kelsey et al., 1988). Being pregnant more than 
once and at an early age reduces the risk of breast cancer. Some studies have shown that 
breast-feeding slightly lowers breast cancer risk, especially if the breast-feeding lasts 1½ 
to 2 years. The use of oral contraceptives at a young age and the use of hormone 
replacement therapy are also known to increase the breast cancer risk.  
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Table 1.1 Risk factors for the development of breast cancer 
 
Risk Factors High risk Low risk Relative risk 
Age at 1st full term pregnancy >30 <20 2-4 
Age at menarche Early Late 1-1.9 
Age at menopause Late  Early 1-1.9 
Family history of premenopausal 
bilateral breast cancer 
Yes  No >4 
Past history of breast cancer  Yes  No >4 
Any 1st degree relative with breast 
cancer 
Yes  No 2-4 
Biopsy showing atypical hyperplasia Yes No >4 
Adapted from (Kelsey et al., 1988) 
 
Table 1.2 Estimated risks for different age group 
 
                 Age  Group (in years)               Estimated Risk 
                 20-29                       1 in 1,900 
                 30-39                       1 in 233 
                 40-49                      1 in 69 
                 50-59                      1 in 38 
                 60-69                      1 in 27 
                 70-79                      1 in 11 
                 ≥ 80                      1 in 10 
 Adapted from Breast Cancer.org, 2012 
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Figure 1.3: Numbers of new cases and age specific incidence rates, by sex, breast 
cancer, UK  
(Adapted from Cancer Research UK, 2011)  
 
 27 
 
 
 
 
 
Figure 1.4: Age specific incidence rate of female breast cancer in United 
Kingdom, 1975-2008 
(Adapted from Cancer Research UK, 2011) 
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The risk of breast cancer appears to be higher in women from more affluent background 
and white women as compared to African-American women. Breast cancer risk increases 
in women who migrated from low risk to high risk countries. Asian, Hispanic, and 
American Indian women have a lower risk of getting breast cancer.  
Various studies have shown that about 5% to 10% of breast cancer cases are hereditary as 
a result of gene mutations. The most common gene mutations are those of the BRCA1 
and BRCA2 genes which lie on chromosome 17q and chromosome 13q respectively. 
Normally, these genes help to prevent cancer by making proteins that keep cells from 
growing abnormally. Over 200 described mutations of these genes exist, each carrying 
different risks of breast cancer. Overall individuals with these gene mutations have up to 
85% chance of getting breast cancer during their lifetime. These genes have been found in 
approximately 85 per cent of families with four or more cases of breast cancer diagnosed 
under the age of 60. Mutation in other genes like p53, Rb and Myc may raise breast 
cancer risk as well. 
Breast cancer risk is higher among women whose first degree blood relatives have this 
disease. The relatives can be either from the maternal or paternal side of the family. Other 
factors associated with increased risk are a previous history of breast cancer or benign 
disease with atypical histology, exposure of breast tissue (chest area) to ionizing radiation 
(particularly before 20 years of age), an increased body size (obesity) as the conversion of 
adrenal androstenedione to oestrone by the aromatase enzyme is related to body weight 
and alcohol consumption.  
 29 
 
1.1.3 Pathology 
The breast is divided into 15-20 lobes composed of lobules embedded in fibro fatty tissue. 
Each lobe is drained by a single collecting duct, formed by coalescence of the ducts of the 
component lobules which in turn converge to open on the summit of the nipple. The 
smallest ducts, closest to the lobules are termed as the terminal ducts and along with the 
lobule form terminal duct –lobular units. The entire breast duct- lobular units is lined by 
two cell types, an inner luminal epithelial cell which differentiates into the milk secreting 
cell and an incomplete outer layer of myoepithelial cells. Basement membrane surrounds 
the epithelial cell layers. Breast cancer arises from the epithelium of the duct system 
extending from the nipple end of major lactiferous ducts to the terminal duct unit in the 
breast lobule. Breast cancer is morphologically described as either invasive or in situ (non 
invasive) carcinoma. A classification of breast carcinoma modified from that of the world 
health organisation is shown in Table 1.3. 
Invasive ductal carcinoma (also known as Not Otherwise Specified-NOS) is the most 
common type and constitutes about 70% of the breast cancer. Lobular carcinoma is the 
second most common and accounts for 10% of breast cancers. A small percentage of 
breast cancers belong to rarer histological variants, usually towards the well-differentiated 
end of the spectrum and hence carrying a better prognosis. These include medullary 
carcinoma with a marked lymphocytic infiltration, colloid or mucinous carcinoma, whose 
cells produce abundant mucin, and tubular carcinoma. 
Inflammatory carcinoma is a fortunately rare, highly aggressive cancer that presents as a 
painful, swollen breast with cutaneous oedema. This is due to blockage of the subdermal 
lymphatic with carcinoma cells.  
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Another variant is the In situ carcinoma in which the malignant cells are confined within 
the myoepithelial layer and basement membrane and hence do not have the metastatic 
potential. This was previously a rare, usually asymptomatic finding in breast biopsy 
specimens, but is becoming increasingly common with the advent of mammographic 
screening. It now accounts for over 20% of cancers detected by screening in the UK. In 
situ carcinoma may be ductal (DCIS) or lobular (LCIS) carcinoma in situ, the latter often 
multifocal and bilateral. Both are precursor of invasive cancer, which will go on to 
develop in at least 20% of cases. DCIS may be classified by the Van Nuys system, which 
combines the patient's age, type of DCIS (high, intermediate and low grade based on 
nuclear atypia) and presence of microcalcification, extent of resection margin and size of 
disease. Patients with a high score benefit from radiotherapy after excision, whereas those 
of low grade, who are completely excised, need no further treatment. 
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Table 1.3 WHO classification of Breast carcinoma 
 
Tumour type  
In situ carcinoma 
In situ ductal carcinoma 
In situ lobular carcinoma 
In situ carcinoma with microinvasion 
8 % 
Infiltrating carcinoma 
Infiltrating ductal carcinoma 
Infiltrating lobular carcinoma 
 
70 % 
10 % 
Carcinoma with particular clinical manifestations 
Pagets disease of the nipple 
Inflammatory carcinoma 
 
1 % - 4 % 
1 % - 5  % 
Others  
Medullary carcinoma 
Mucoid / colloid carcinoma 
Tubular carcinoma 
Adenoid cystic carcinoma 
3 % - 10 % 
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1.1.3.1 Tumour Grade 
Grade refers to how similar the tumour is to the surrounding normal breast tissue. 
Different grading systems have been proposed in the past but the generally accepted 
system is the modified Bloom and Richardson Grading System of breast cancer [based on 
mitotic index, tubule formation and nuclear pleomorphism and correlates with outcome] 
which is detailed in Table 1.4. 
 
1.1.4 Diagnosis and Staging  
1.1.4.1 Diagnosis 
Breast cancer can arise from any portion of the breast, including the axillary tail.  It most 
commonly arises in the upper outer quadrant. Breast cancer usually present as: 
• Breast lump 
• Bloody nipple discharge 
• Skin changes like tethering, peau d’orange appearance, indrawing of the nipple, 
nipple eczema and rarely frank ulceration. 
• Mammographic screening abnormalities 
Breast cancer is diagnosed by triple assessment which includes clinical evaluation, 
imaging (ultrasound <35 years old or mammography >35 years old) and cytological or 
histological examination.  
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Table1.4: Modified Bloom and Richardson Grading System of breast cancer 
 
Tubule Formation 
(% of tumour exhibiting gland formation) 
>75% of tumour 
10- 75% of tumour 
<10% of tumour 
 
 
1 
2 
3 
Pleomorphism (Variation in size and 
shape of nuclei) 
Mild 
Moderate 
Marked 
 
 
1 
2 
3 
Mitotic activity  
<6 mitosis/ 10hpf 
7- 15 mitosis/ 10hpf 
>15 mitosis/ 10hpf 
 
1 
2 
3 
Total Score is derived from adding scores 
for the 3 parameters. The score varies 
from 3- 9. 
Grade 1 (well differentiated ) 
Grade 2 (moderately differentiated) 
Grade 3  (poorly differentiated) 
 
 
 
3-5 
6-7 
8-9 
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1.1.4.2 Staging 
Following diagnosis the stage of the disease is determined using various staging system 
and the most commonly used staging system is the Tumour size-Node- Metastasis (TNM) 
classification.  
T: Tumour Size 
The letter T followed by a number from 0 to 4 describes the tumour’s size and whether it 
has spread to the skin or chest wall under the breast. Higher T numbers indicate a larger 
tumour and/or more extensive spread to tissues surrounding the breast.  
• TX: Tumour cannot be assessed  
• T0: No evidence of a tumour  
• Tis: Insitu carcinoma-Ductal carcinoma in situ or Lobular carcinoma in  situ 
• T1: Tumour < 2 cm in diameter  
• T2: Tumour between 2 and 5 cm in diameter  
• T3: Tumour >5 cm in diameter 
• T4: Tumour of any size, fixed to the chest wall  
N: Palpable Nodes 
The letter N followed by a number from 0 to 3 indicates whether the cancer has spread to 
lymph nodes. 
• NX: Lymph nodes cannot be assessed  
• N0: No lymph node involvement 
• N1: Ipsilateral axillary lymph nodes involvement, mobile 
• N2: Spread to ipsilateral lymph nodes and fixed  
• N3: Spread to the ipsilateral internal mammary lymph nodes or the ipsilateral 
supraclavicular lymph nodes  
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M: Metastasis 
The letter M followed by a 0 or 1 indicates whether or not the cancer has metastasized 
(spread) to distant organs (i.e., the lungs or bones).  
• MX: Metastasis cannot be assessed  
• M0: No distant metastasis  
• M1: Distant metastasis  
Staging of Breast Cancer 
 
The American Joint Committee on Cancer (AJCC) staging of a breast cancer describes its 
size and the extent to which it has spread. The staging system ranges from Stage 0 to 
Stage IV as shown in table 1.5. 
 
Table 1.5: Stages of Breast Cancer 
 
Stage Tumour Size Lymph Node Involvement Metastasis 
0 Tis N0 M0 
I T1 N0 M0 
II A 
 
II B 
 
T0, T1 
T2 
T2 
T3 
N1 
N0 
N1 
N0 
M0 
M0 
M0 
M0 
III A  
 
III B 
 
 
T0, T1, T2 
T3 
T4 
Any T 
N2 
N1, N2 
Any N 
N3 
M0 
M0 
M0 
M0 
IV Any T Any N M1 
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1.1.4.3 Nottingham Prognostic Index (NPI) 
Like all types of cancer, breast cancer is an unpredictable condition and no one can be 
absolutely certain of the outcome of treatment. The important prognostic factors are 
lymph node involvement, tumour size and tumour grade. The Nottingham prognostic 
index (NPI) (Galea et al., 1992) is a predictive index of the clinical outcome of breast 
cancer which has been devised combining the following factors: tumour size, node 
involvement and modified Scarff Bloom Richardson (SBR) grading system. The NPI can 
be calculated as: 
NPI = 0.2 x tumour size (cm) + lymph node stage + histological tumour grade 
The lymph node stage is 1 (if there are no nodes affected), 2 (if up to 3 nodes are 
affected) or 3 (if more than 3 nodes are affected). Similarly the tumour grade is scored as 
1 (for grade I), 2 (for a grade II) or 3 (for a grade III). 
Applying the formula gives scores which fall into three bands: 
• a score of less than 3.4 - suggests a good outcome with a 80% 15 year survival  
• a score of between 3.4 to 5.4 - suggests an intermediate level with a 42% 15 year 
survival 
• A score of more than 5.4 - suggests a poor outcome with a 13% 15 year survivial. 
Beside this there are other important independent prognostic variables like 
lymphovascular invasion and oestrogen and progesterone receptor status which are useful 
in determining the clinical outcome of the breast cancer. The presence or absence of 
lymphovascular invasion is considered to be useful in predicting local recurrences. 
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1.1.5 Treatment of Breast Cancer 
 
Treatment of breast cancer largely depends upon clinical stage of the disease at the time 
of presentation. Surgery remains the cornerstone of breast cancer management and has 
been the primary treatment for breast cancer patient for more than 100 years. Radical 
surgery for breast cancer has been the ‘gold standard’ in the past. Over the last two 
decades, various trials including the National Surgical Adjuvant Breast and Bowel Project 
–NSABP-06 (Fisher et al., 1992 ) have demonstrated no difference in the disease free 
survival between  early breast cancer patients who had  conservative breast surgery and 
those who had mastectomy. Wide local excision of the tumour followed by radiotherapy 
is now well accepted practice for early breast cancer. Breast cancer commonly spreads to 
the regional axillary lymph nodes and occasionally the tumour cells may spread to the 
internal mammary lymph nodes. Since the majority of tumour spread is to the axilla, 
Axillary Clearance and the minimally invasive procedure Sentinel Lymph Node Biopsy 
(SLNB) constitutes a part of standard treatment for breast cancer. Systemic therapy which 
includes chemotherapy or hormonal therapy is given if there are associated poor 
prognostic factors such as lymph node metastasis and high tumour grade as there is 
increase chance of local or metastatic recurrence. On the other hand in metastatic breast 
cancer surgery play a very limited role and is usually treated by either radiotherapy or 
systemic chemotherapy for symptomatic relief. 
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1.1.5.1 Endocrine therapy 
 
Reproductive and certain other sensitive tissues like mammary adipose tissue possess 
high affinity protein receptors for oestrogen and progesterone. Specific receptors for both 
hormones may be present in tumour tissue of mammary origin and play key roles in both 
normal breast development and breast cancer progression. These receptor proteins are 
activated when occupied by their specific hormone ligand leading to the induction of 
cellular genes, including those that may encode critical enzymes and secrete peptide 
growth factors. 
Oestrogen receptors (ER) are intracellular DNA-binding transcription protein expressed 
in different tissue types including endometrium, breast cancer cells and ovarian stroma 
cells.  There are two different forms of ER, referred as ERα and ERβ which  are encoded 
by seperate genes ESR1 and ESR2 on the 6q25.1 and 14q23.2 chromosomes respectively. 
Hormone-activated estrogen receptors are coexpressed in many cell types and may form 
homodimers or heterodimers with each other (Li et al., 2004). ER interacts with 
transcriptional coactivators and corepressors responsible for tissue selective agonistic or 
antagonistic effect of the ligands like oestrogen and tamoxifen (Deroo et al., 2006). ER 
binds to the oestrogen and this complex subsequently binds to the specific sequences of 
DNA which in turn recruits other proteins responsible for the proliferation of mammary 
cells. ER form complexes with G proteins and tyrosine kinases like EGFR and IGF-1 
(Levin ER, 2005; Zivadinovic et al., 2005) and the signals are sent to the nucleus through 
the mitogen activated protein kinase (MAPK/ERK) pathway and phosphoinositide 3- 
kinase (Pl3K/AKT) pathway (Kato et al.,1995).  
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HER2 (Human Epidermal Growth Factor Receptor 2) protein also known as ErbB-2 is a 
member of the epidermal growth factor receptor (EGFR/ErbB) familyof proto-oncogene. 
HER2 is encoded by ERBB2 proto-oncogene located at the long arm of human 
chromosome 17. It has been shown that over-expression of HER2 play an important role 
in the pathogenesis and progression of breast cancer and recently has evolved as an 
important biomarker  and therapy target in patients with breast cancer (Saini et al., 2011; 
Eccles SA., 2011; Moasser MM., 2007). 
The clinical importance of amplification of HER2 in breast cancer was first recognised in 
1987 (Slamon et al., 1987). Amplification of the HER-2 was a significant predictor of 
overall survival and time to relapse in patients with breast cancer and is associated with 
increased recurrence and poor prognosis (Slamon et al., 1987; Barnes DM., 1993). Over-
expression of HER2 occurs in approximately 15% to 20%  of breast cancer and is 
measured using immunohistochemistry or fluorescence in situ hybridisation technique 
(Belengeanu et al., 2010). HER2  activates various signaling pathways like mitogen 
activated protein kinase (MAPK), phosphoinositide 3- kinase (P13K/ AKT) and protein 
kinase C (PKC) pathways  (Roy et al., 2009) leading to proliferation and uncontrolled cell 
growth (Nagy et al., 1999).  
Endocrine therapy for breast cancer involves selective oestogen receptor modulators like 
tamoxifen and aromatase inhibitors such as anastozole and letrozole. ER status is used to 
determine sensitivity of breast cancer to tamoxifen and aromatase inhibitors. (Clemons et 
al., 2002). 
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Surgically induced menopause in the form of bilateral oophrectomy became the first 
effective means to control advanced breast cancer. Over the last two decades hormonal 
manipulation for the treatment of breast cancer has been simplified by the introduction of 
tamoxifen and aromatase inhibitors. This is assessed by measuring oestrogen and 
progesterone receptor status by immunohistochemistry of the resected tumour and 
reported using a standardised technique such as the Allred scoring system. This assay 
may be done on either frozen or paraffin embedded tumour sections. In general, if greater 
than 10% of tumour cells stain positive for the nuclear receptor, the assay is reported as 
positive and a response to hormonal therapy is likely. The majority of human breast 
cancer contain hormonal receptor either oestrogen or progesterone or both. 
Approximately 70% of primary breast cancers express ER (Oestrogen Receptor), and over 
half of this also expresses PgR (Progesterone Receptor). The presence of oestrogen 
receptor predicts the clinical response to all types of endocrine therapies including the 
hormonal therapy. Treatment aimed at inhibiting the action of ER represents a highly 
successful example of targeted therapy for clinical breast cancer (Campos et al., 2003).  
ER positive tumours have a 5-10% better chance of survival than ER negative tumours. In 
addition patients with ER positive tumours respond well to anti-oestrogen treatment with 
better clinical outcome as compared to ER negative tumours (Dowsett et al., 2006). 
Patients with both ER and PgR positive have better prognosis than those with ER positive 
but PgR negative tumours (Bardou et al., 2003).  It has been demonstrated that patients 
with ER+/HER2+ compared with ER-/HER2+ breast cancers may benefit more from 
drugs that inhibit the PI3K/AKT molecular pathway (Loi et al., 2009). The expression of 
HER2 is regulated by signaling through estrogen receptors. It has been shown that 
oestradiol and tamoxifen acting through the estrogen receptor down-regulate the 
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expression of HER2. (Hurtado et al., 2008). Low ER or PgR or high HER-2 expression is 
associated with a high risk of recurrence with either anastrozole or tamoxifen 
Tamoxifen is an oestrogen receptor modulator and acts as a weak agonist / antagonist. It 
acts as a competitive antagonist of oestrogen activity in the breast tissue but not in other 
oestrogen sensitive tissues.  Tamoxifen reduces the risk of local recurrence by 25% and 
mortality by 17% in oestrogen/ progesterone receptor- positive breast cancer patients. 
Aromatase inhibitors are agents that block the conversion of androstenedione to oestrone 
by inhibiting the aromatase enzyme. Aromatase inhibitors like anastrozole and Letrozole 
are now well established proven adjuvant endocrine therapy in the treatment of breast 
cancer. Forbes et al., 2008 reported significant improvement in disease-free survival and 
risk of disease recurrence in ER positive breast cancer patients treated with anastrozole. 
 
1.1.6 Prognosis 
The prognosis of breast cancer has been improving over last three decades and more 
women are being successfully treated than ever before. As Shown in figure1.5 the 
estimated relative five-year survival rate for women diagnosed with breast cancer in 
England in 2001-2006 was 82%, compared with only 52% for women diagnosed in early 
1970s (Cancer Research UK, 2011).The estimated relative twenty year survival rate for 
women with breast cancer has gone from 44% in the early 1990s to 64% in 2003 (Cancer 
Research UK, 2011). As figure1.6 shows, breast cancer survival rates are higher in 
women diagnosed in their 50s and 60s than for either younger or older women. The 
maximum improvement in five-year survival have been for women aged 50-69 years 
(Cancer Research UK, 2011). 
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Prognostic indicators serve as a guide for clinical decision and estimates of outcome. The 
prognosis depends on the invasiveness and the metastatic potential of the breast cancer. In 
an attempt to define which tumours will behave aggressively, a host of prognostic factors 
has been described. These include tumour size, lymph node status, histological grade of 
the tumour, hormone receptor status, measures of tumour proliferation such as S-Phase 
fraction and thymidine labelling index, growth factor analysis and oncogene or oncogene 
product measurements. Breast cancer spreads via the lymphatic system and primarily 
spreads to axillary lymph nodes.  The best indicators of likely prognosis in breast cancer 
are the histological grade, tumour size and the lymph node status. The regional lymph 
node status remains the single most important prognostic factor (Fisher et al., 1983 ) and 
a positive correlation has been noted between the number of lymph nodes involved and 
poor prognosis (Carter et al., 1989). Patients with ≥ 5 positive nodes have a  5 –year 
survival of less than 20% (Fisher et al., 1983 ). Various other studies have shown that the 
prognosis for node-negative patients is better than those with node positive patients (Kim 
et al., 2011; Carter et al., 1989; Quiet et al., 1995; Saimura et al., 1999). 
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Figure 1.5: Age-standardised five-year relative survival rate, female breast 
cancer, England and Wales, 1971-2006  
(Adapted from Cancer Research UK, 2011) 
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Figure 1.6: Relative five, ten, fifteen and twenty year survival (%) breast cancer, 
by age at diagnosis, England and Wales, 2001-2003 
(Adapted from Cancer Research UK, 2011) 
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1.2 Transcription factor:  
Transcription is defined as the synthesis of RNA from a DNA template. It consists of 
three steps:  
Initiation- In this step RNA polymerase binds to double stranded DNA (promoter). 
Promoter is defined as the DNA sequence containing binding sites for RNA polymerase 
and the transcription factors necessary for normal transcription. 
Elongation- In this step single stranded DNA is formed by the addition of nucleotides to 
the 3’end of the polynucleotide chain. 
Termination- In this step the process of transcription terminates the recognition of 
transcription termination sequence and the RNA polymerase is released.  
The process of transcription requires other associated gene regulatory proteins 
(transcription factors) along with RNA polymerase. A transcription factor is a protein that 
binds DNA at a specific promoter or enhancer region or site, where it regulates 
transcription. These proteins are primarily involved in the initiation stage of RNA 
transcription and play an important role in determining where the DNA chain becomes 
unzipped, creating a single strand to which RNA can be attached. These proteins can be 
selectively activated or deactivated by other proteins and binds to DNA at a sequence 
specific site and regulates transcription. Different DNA binding motifs found in 
transcription factors are as follows:  
• Leucine zippers DNA binding motif: helps in associating the transcription 
factors with each other. Examples of this group includes CREB family of 
transcription factors and C/EBP. 
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• Zinc fingers: are protein motifs act as a structural platform for DNA binding by 
the coordination of one or more zinc ions. Example of Zinc fingers includes SP1 
TFIIIA and oestrogen receptors 
• bHLH (Basic-helix-loop- helix): binds DNA with two alpha helices containing 
basic amino acid residues. Example includes Myc protein, E12/E47 and myogenic 
regulatory factors. 
• HTH (Helix- turn- helix): binds the major groove of the DNA. Example includes 
Myb and ETS protein. 
There are three classes of transcription factors as described below: 
• General transcription factors: These are ubiquitous factors and are involved in 
the formation of a preinitiation complex by interacting with the promoter region 
surrounding the transcription start site. Examples of general transcription factors 
are RNA polymerase II holoenzyme (RNAPII), TFIIA, TFIIB, TFIID, TFIIE, 
TFIIF and TFIIH. 
• Upstream transcription factors: These are unregulated proteins which bind to 
initiation site to activate or inhibit transcription. These factors increase the 
efficiency of transcription initiation. Examples of upstream transcription factors 
are SP-1, AP-1, ATF/CREB, c-myc and C/EBP 
• Inducible transcription factors: These factors act in the same manner as an 
upstream factor but require activation or inhibition before binding to transcription 
site. Examples of inducible transcription factors are c-Jun, c-Fos, JunD, JunB and 
FosB  
 47 
 
1.2.1 Functions of transcription factors 
• Binds to RNA polymerase 
• Binds to another transcription factor 
• Binds to cis- acting DNA sequences 
 
1.3 Transcription factors and breast cancer 
Transcription factors helps in various physiological processes including DNA replication, 
cell growth and cellular differentiation. Hence the defect in transcriptional factors either 
inherited or acquired may contribute to various types of malignancy including breast 
cancer. Transcription factors when genomically altered have the potential oncogenic role 
in various malignancy including lymphomas, leukaemia’s and breast cancer. 
Transcription factors represent prime targets for disruption in the process of 
tumourigenesis as they possess specific structural features that encode transactivating or 
repressing functions as well as dimerization, nuclear localization and DNA binding 
functions.  These transcription factors are cell cycle associated and are expressed 
ubiquitously in various malignant tumours rather than lineage restricted expression 
(Rabbitts et al., 1994). Some tumours like lymphomas and childhood tumours can have 
lineage- restricted transcription factors abnormality leading to dysregulated cell growth 
(Look et al., 1997). It has been suggested that the ubiquitously expressed transcription 
factor can achieve lineage restricted gene control and upon disruption or activation can 
lead to abnormal cell growth. Various proto-oncogenes and anti-oncogenes are known to 
encode proteins which act as transcriptional regulators. These proteins which include  
 
 48 
 
oncoproteins like Myc and Myb and tumour suppressor proteins like Rb and p53 are cell 
cycle associated and are ubiquitously expressed. 
Breast cancer results from acquired or inherited gene defects leading to genomic 
instability and hence the tumour growth due to increased proliferation of transformed 
mammary cells (Jackson et al., 1998; Loeb et al., 1998). Various oncogenes and tumour 
suppressor genes leading to abnormal transcription factor expression in breast tumours are 
Myc, Rb, and p53.  
Various defective gene controlling mechanisms resulting in the expression of abnormal 
transcriptional factors in breast tumourigenesis are as follows: 
• Growth dysregulation by defective transcription factor expression 
• Post- translational activation of transcription factors mediating breast 
tumourigenesis 
• Breast tumour co regulators and cooperating transcription factors 
• Transcriptional silencing in breast tumours 
 
1.3.1 Growth dysregulation by defective transcription factor expression  
Defects in ER, Myc, Rb and p53 contribute to a common growth dysregulatory 
mechanism that drives the uncontrolled cellular proliferation underlying breast tumours. 
The growth dysregulating consequences of overexpressed oestrogen receptor (ER) 
represent the most common transcriptional defect found in breast cancer and occur in 
more than 50% of all newly diagnosed breast cancer (Tripathy et al., 1992). It is an 
important molecular target for the treatment of this malignancy. 
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The overexpression and transcriptional upregulation of Myc occurs in 30% of primary 
breast cancers (Escot et al.,  1986 ) and underexpression of p53 due to various genomic 
point mutations occurs in 20-40% of breast cancer (Hartmann et al., 1997). Lania et al. 
have shown the relationship between these transcriptional factors and the regulation of 
cell cycle progression  between G1 and S phases leading to loss of G1 –S cell cycle 
control (Lania et al.,  1999).  
 
1.3.2 Post translational activation of transcription factors mediating breast 
tumourigenesis 
Expression of transcription factors is dependent on both transcriptional and post 
translational control. Tumourigenesis can be mediated by disturbances in the post 
translational modification of the transcriptional factors, as the control of the genes they 
regulate may be influenced by the post translational activating mechanisms. These 
activating mechanisms may be ligand activated as characteristically occurs with members 
of the oestrogen receptor (ER) family or by intracellular signalling pathways that produce 
covalent modifications in the structure of the transcription factors or by Mitogen- 
activated protein kinase (MAPK) (Kato et al., 1995; Katzenellenbogen et al., 1997; Kato 
et al., 2001). 
 
1.3.3 Breast tumour coregulators and cooperating transcription factors 
Most transcription factors, including the members of the steroid receptor superfamily, 
work to regulate gene expression in conjunction with co-regulatory factors known as 
coactivators or corepressors. Amplification and overexpression of the coregulators has  
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been found in a significant proportion of primary breast tumours (Horwitz et al., 1996; 
Smith et al., 1997). 
 
1.3.4 Transcriptional silencing in breast tumours 
Gene repression by DNA hypermethylation with the formation of M5C in gene regulatory 
region may represent part of a more fundamental imbalance in genomic methylation 
associated with breast tumours (Baylin et al., 1998). This hypermethylation mechanism 
has been shown to lead to transcriptional repression of tumour suppressor genes encoding 
various transcription factors like Rb, VHL and E- cadherin. 
 
 1.4 CREB/ ATF Family 
As described earlier transcription factors are divided into various families such as basic- 
helix- loop- helix (bHLH), leucine zipper with basic domain (bZip), zinc- finger, 
homeobox (HOX) and Ets factors. cAMP responsive element binding (CREB)/ Activating 
transcription factor (ATF) protein belongs to a subfamily of the bzip family of 
transcription factors. The cAMP transcription factors belong to a multigene family with 
several isoforms that may function as transcriptional activators or repressors (Hai et al., 
1989). The common motif shared by them is a basic domain – leucine zipper (bZip) (Hai 
et al., 1989) at the carboxyl- terminal end that promotes dimmer formation. This family of 
transcription factors is a component of intricate intracellular signaling pathway that is 
important for regulating biological functions ranging from spermatogenesis to circadian 
rhythms and memory (Silva et al.,  1998). 
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Activating transcription factor (ATF) was first isolated and named by Lee et al. in 1987 
(referred to proteins that bind to adenovirus early promoters E2, E3 and E4)(Lee et al., 
1987). cAMP responsive element binding protein (CREB) was named in 1987 to refer to 
proteins that bind to the cAMP responsive element (CRE) on the somatostatin promoter 
(Montminy et al., 1987). The CREB/ ATF family of transcription factor was identified by 
their ability to bind to the consensus CRE/ ATF site “TGACGTCA” (Montminy et al.,. 
1987).  Hai et al. identified cDNAs encoding 8 different human CREB/ ATF binding 
proteins (Hai et al., 1989). At present there are over 20 different CREB/ ATF cDNAs 
which have been identified and described. All members of this family share significant 
sequence similarity within a leucine zipper DNA- binding motif and an adjacent basic 
region. The members are grouped into subfamilies based on sequence homology outside 
the bzip domain (amino acid similarity).  
CREB 1 is mapped to human chromosome 2q32.3-q34. The nomenclature for this family 
of proteins is confusing. Over the year’s cDNA encoding homologous or identical 
proteins encoding bZip DNA binding domain were isolated by different laboratories and 
given different names.  In various literatures alternative names were used to identify the 
same protein (Table 1.6) as well as the same name was used to refer to different proteins. 
As for instance CREB2 has been used to refer to three different proteins: CRE-BP1 
(ATF2) (Flint et al., 1991), ATF4 (Karpinski et al., 1992), and an alternatively spliced 
CREB (Yoshimura et al., 1990 ). Hence to ensure the identity of a given protein, the best 
way is to inspect its amino acid sequence. These proteins are therefore grouped into 
subgroups according to amino acid similarity.  
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Table 1.6: The mammalian CREB/ ATF family of transcription factors 
(Hai et al., 2001) 
Subgroup Members Alternative names 
CREB • CREB-1 
• CREM 
• ATF-1 
ATF-47 
 
TREB-36,TCRATF-1, 
ATF-43 
CRE-BP-1 • CRE-BP-1 
 
• ATFa 
• CRE-BPa 
ATF-2, HB-16, TREB, 
TCR-ATF-2, mXBP 
ATF-3 • ATF-3 
 
• JDP-2 
LRF-1, LRG-21, CRG-5, 
TI-241 
ATF-4 • ATF-4 
 
• ATFx 
CREB-2, TAXREB-67, 
mATF4, C/ATF, mTR-67. 
hATF-5 
ATF-6 • ATF-6 
• CREB-RP 
ATF-6α 
G-13, ATF-6β 
B-ATF • B-ATF 
• JDP-1 
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1.4.1 Cross talk between CREB/ ATF, AP1 and C/EBP Proteins 
Besides CREB/ ATF, other proteins also contain the bZip DNA binding domain; they 
include the AP1 and C/EBP families of proteins (Cao et al., 1991; Yeh et al., 1995). This 
family of proteins can cross bind to each others consensus sites (Table 1.7) and can form 
heterodimers with members of another family. These proteins can form selective 
heterodimers with ATF2 (Hai et al., 1989), cJun (Hai et al., 1991; Hsu et al., 1992) Jun B 
(Hsu et al., 1992) and JunD (Chu et al., 1994; Fawcett et al., 1999). These heterodimers 
can act as activators or repressors depending on the promoter. Besides this, members of 
one family can regulate transcription in manner characteristics of the other family like Jun 
protein regulate the proencephalin promoter in a cAMP –dependent manner (Kobierski et 
al., 1991 ) and C/EBP protein regulates certain promoters via a CRE site instead of a 
C/EBP site (Park et al., 1993). Examples of crosstalk between CREB/ ATF, AP1 and 
C/EBP are shown in the table1.7. 
Table1.7: Examples of crosstalk between CREB/ ATF, AP1 and C/EBP 
 
Cross family binding 
CREB/ ATF proteins bind to the AP1 consensus (Hai et al., 1991; Masquilier et al., 
1992) 
AP1 proteins bind to the CRE/ ATF consensus (Ryseck et al., 1991) 
C/EBP proteins bind to the CRE/ ATF consensus (Bakker et al., 1991) 
 Cross family Heterodimer formation 
CREB/ ATF and AP1 (Benbrook et al., 1990; Chatton et al., 1994) 
AP1 and C/EBP (Hsu et al., 1994 ) 
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1.4.2 Mode of action of CREB 
CREB is a 43 kDa basic /leucine zipper (bZip) transcription factor that regulates gene 
expression through the activation of cAMP dependent or independent signal transduction 
pathways. The leucine zipper is needed for dimerization whereas the adjacent basic 
domain mediates the contact with DNA (De Cesare et al., 2000). These transcription 
factors acts through cAMP (Montminy et al., 1997) which is an important intracellular 
second messenger for a number of hormones and mediates the transcriptional induction of 
many genes. It binds to cAMP responsive element (CRE) 5’-TGACGTCA-3’ (Deutsch et 
al., 1988) and activates transcription in response to a variety of extracellular signals 
including neurotransmitters, hormones, membrane depolarization, and growth and 
neurotrophic factors. The unique aspect of the genes encoding CREB and other members 
of this family is that they can originate different isoforms by mechanisms of alternative 
exon splicing, alternative promoter usage and autoregulation of promoters (De Cesare et 
al., 2000). Some isoforms act as activator of transcription such as phosphorylated CREB 
whereas others such as the inducible cAMP Early repressor (ICER) act as repressors. 
Activation of CREB requires phosphorylation by cAMP- dependent protein kinase at 
serine-119 and serine-133 for interaction with DNA and RNA polymerase ІІ (Gonzalez et 
al., 1989; Lee et al., 1995; Wong et al., 1995; Shaywitz et al., 1999; Johannessen et al., 
2007). Phosphorylation occurs via p44 / 42 MAP kinase and p90RSK and also via p38 
MAP kinase and MSK 1. Although CREB binds to DNA independent of its 
phosphorylation state, only the phosphorylated form is competent as a transcription 
factor. P- CREB in turn increases the expression of the CREB gene itself as well as of the 
repressor ICER upon binding to CRE sequences in the promoter region of these genes  
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(De Cesare et al., 2000). There are evidence suggesting that the CREB/ ATF proteins 
binds to cAMP response element (CRE) consensus sequence in target genes as a 
homodimer or heterodimer with other members of the family or with other bZip proteins 
like fos and jun family of proteins (AP-1) (Chinenov et al., 2001).  These alter DNA 
binding specificity and transcriptional activity and hence the gene expression. These bZip 
proteins can also bind to each other’s consensus site and regulate transcription similar to 
other family proteins.  
 
1.5 CREB/ ATF and Malignancy 
The cAMP response element – binding protein (CREB) overexpression is associated with 
increased risk of relapse of acute myeloid leukemia. CREB promotes abnormal 
proliferation, cell cycle progression and survival of myeloid cells through upregulation of 
specific target genes. Activation of CREB is downstream of mitogen activated protein 
kinase kinase (MAKK) and pp90 ribosomal S6 kinase (RSK) – dependent pathways in 
myeloid cells (Lee et al., 1995; Kwon et al., 2000). CREB also induces proliferation of T 
cells in response to a variety of stimuli (Kuo et al., 1999). CREB is expressed in the 
normal adrenal cortex and in adrenal adenomas but no CREB transcript is detectable in 
adrenal carcinoma and is reduced in thyroid carcinoma (Reincke et al., 1997).  
CREB mediates cellular responses to various mitogens and stressors.  Various stress 
signals, growth factors and kinases promote phosphorylation –mediated activation of the 
CREB, involved in glial cell fate determination (Bayatti et al., 2001). CREB has an 
antimitogenic role in astrocytes and suppresses the proliferation of glioblastoma through 
an intrinsic transcriptional regulation mechanism of stress induced acetylcholinestrase  
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variant, AChE-R.  CREB promotes proliferation and survival of neurons and glial cells in 
the injured brain (Ong et al., 2000) and mediates cell viability during early embryonic 
development (Bleckmann et al., 2002). 
Various growth factors, stress signals and kinases including PKA, PKC, calcium / 
calmodulin kinase 2 and MAPK activated protein, promote CREB activation by Ser 133 
phosphorylation  resulting in diverse cellular outcomes including cell proliferation (Goren 
et al., 2001 ) (Table 1.8). PKC – mediated CREB activation induced proliferation of early 
oligodendrocytes (Afshari et al., 2001). PKA – dependent CREB activation promotes 
astroglia differentiation (Bayatti et al., 2001) and is required for Shwann cell proliferation 
(Lee et al., 1999). 
 
Table1.8 Extra cellular regulations of CREB/ ATF proteins 
Member  Mode of regulation Regulators 
CREB, CREM, ATF1 Post translational cAMP/PKA (Liu et al., 1993) 
calcium  ionophores (Montminy 
et al., 1997)  
CRE-BP1, ATF2 Post translational 
RNA level 
TPA stress kinases (Gupta et al., 
1995)   
ATF3 Post translational 
RNA level 
HTLV-1 Tax (Low et al., 1994)   
PKA (Chu et al., 1994) Hepatitis 
virus X protein (Barnabas et al., 
1997 ) 
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1.6 CREB/ ATF in other conditions 
 This family of transcription factors is a part of intricate intracellular signaling pathway 
that is required in the regulation of various biological and cellular functions including cell 
survival, spermatogenesis, glucose homeostasis, circadian rhythm, memory and neuronal 
plasticity (Barton et al., 1996; Silva et al., 1998; De Cesare et al., 1999; Bonni et al., 
1999; Travnickova-Bendova et al., 2002). Its activity is dependent on serine -133 
phosphorylation, which is catalysed by various groups of serine/ threonine kinases 
including calcium/ calmoudlin-dependent protein kinases, mitogen – activated protein 
kinases( MAPK’S ), protein kinase A, protein kinase G and PP90 ribosomal S6 kinase 
(Gonzalez et al., 1989; Sheng  et al., 1991; Tan  et al., 1996; Xing  et al., 1996; Du et al., 
1998). It is also activated in response to a broad spectrum of stimulant in different cell 
types (De Cesare  et al., 1999; Shaywitz  et al., 1999).  Known target genes are induced in 
response to CREB activation in other systems. Cyclin A 1 has been reported to be a 
CREB target gene and regulates G1to S transition through activation of CDK2 (Woo and 
Poon et al., 2003). CREB directly binds the CRE in the cyclin A1 upon activation of 
CREB (Deutsch et al., 1988; Mayr et al., 2001; Kothapalli et al., 2003). CREB 
overexpression leads to upregulation of a CREB target gene, cyclin A1, and hence 
promoting aberrant cellular proliferation. CREB/ ATF protein is involved in both the 
positive and negative regulation of smooth muscle cell growth and motility. ATF-1 
mediates protease activated receptor-1 induced DNA synthesis in vascular smooth muscle 
cells (Ghosh et al., 2002).  CREB protein mediates thrombin (Tokunou et al., 2001) and 
angiotensin 2 (Funakoshi et al., 2002)induced proliferation of vascular smooth muscle 
cells.  CREB mediates Alpha tumour necrosis factor (α TNF) induced vascular smooth  
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muscle migration. CREB mediates Cycloxygenase induced vascular smooth muscle cells 
motility (Reddy et al., 2002) whereas its activation by Ser – 133 phosphorylation leads to 
decrease expression of multiple cell cycle regulatory genes and hence reduced 
proliferation (Klemm et al., 2001). These differential roles of CREB-1 in the smooth 
muscle cells growth and motility may reflect its coupling to various signaling pathways 
targeting either the stimulation or suppression of growth and motility and therefore can 
function either as an inducer or as a suppressor of gene expression.  
CREB plays a key role in the development of different neuronal cells and is activated by a 
variety of signaling molecule. CREB enhances both proliferation and survival of neuronal 
cells (Riccio et al., 1999 ; Monti et al., 2002; Lonze et al., 2002 ). CREB 1 interacts with 
CRE-11 in the SMN promoter and its overexpression upregulates SMN promoter activity. 
CREB has been shown to be a critical regulator of proliferation in normal neuronal 
development and plays an important role in learning and memory (Shaywitz et al., 1999; 
Mayr et al., 2001 ). CREB knock out mice show diminished learning ability. 
 
1.7 ATF 3 
ATF 3 has been implicated in various physiological and pathological processes including 
stress response, HBV-mediated processes and tumourigenecity. ATF3 was first isolated a 
decade ago, and since then several studies had shown that it can be induced by various 
stress signals. ATF3 is regulated by multiple signaling pathways in signal and cell type- 
dependent manners. ATF 3 interacts with the HTLV-1 Tax protein leading to increase 
transcriptional repression activity (Barnabas et al., 1997 ). ATF3 interacts with the 
hepatitis B virus X protein which is implicated in HBV mediated hepatocarcinogenesis 
 59 
and apoptosis (Table 1.8). Besides this ATF3 play a role in metastatic processes in 
melanoma and has a tumourigenecity- inhibiting effect on the HT29 colon cancer cells 
(Ishiguro et al., 2000).  
ATF3 is the immediate early gene which is induced by various extracellular signals. In 
animal models ATF3 is induced in the heart by myocardial ischaemia and in the liver by 
hepatic ischaemia and partial hepatectomy. In cultured cells ATF3 is induced by a variety 
of signals such as ultraviolet rays and ionizing radiation and cytokines. Allen and 
Jennings demonstrated that ATF3 is induced during pancreatic stress such as partial 
pancreatectomy and ischemia – reperfusion of the pancreas(Allen-Jennings et al., 2001). 
In most systems ATF3 mRNA increases shortly after the exposure of cells to the signals. 
Several genes have been implicated to be the targets like gadd153/chop10 (Wolfgang et 
al., 1997; Fawcett et al., 1999), E- selectin (Nawa et al., 2000 ) and phosphoenolpyruvate 
carboxykinase (Allen-Jennings et al., 2002 ).  
ATF3 gene is induced in a variety of cell types by many stress signals suggesting that 
ATF3 is a key regulator in cellular stress responses. Although the induction of ATF3 gene 
is neither tissue nor stimulus – specific, it is shown that this also induce cellular damage 
(Chen et al., 1996; Tsujino et al., 2000). It has been suggested that ATF3 appears to be 
part of the cellular response that leads to poor outcomes. Allen and Jennings showed that 
in transgenic mice expressing ATF3 in liver results in liver dysfunction and reduced 
expression of gluconeogenic genes (Allen-Jennings et al., 2001). Okamoto demonstrated 
that in transgenic mice expressing ATF3 in the heart have conduction abnormality and 
contractile dysfunction (Okamoto et al., 2001).  
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1.8 CREB/ ATF in Breast Cancer 
1.8.1 Aromatase expression in breast cancer tissue 
Oestrogen is a steroidal hormone which is involved in various reproductive and metabolic 
processes. Pathologically, oestrogen is the primary hormonal factor that stimulates growth 
of hormone-dependent breast cancer. Approximately 75% of all breast cancers are 
hormone dependent of which 50% - 60% of premenopausal and 70% - 75% of 
postmenopausal patients has oestrogen-dependent breast cancer. The effects of oestrogen 
on breast cancer cells are predominantly mediated via interaction with the oestrogen 
receptor (ER) which inturn induces the expression of peptide growth factors that are 
responsible for the proliferation of cancer cells. 
Oestrogen biosynthesis from C19 steroids is catalysed by the enzyme aromatase 
cytochrome P450. Aromatase catalyzes three consecutive hydroxylation reactions 
converting androstenedione and testosterone to oestrone and oestradiol respectively. 
Since aromatase is the enzyme necessary for the synthesis of oestrogens, and oestrogen 
plays a major role in the development of breast cancer, aberrant expression of aromatase 
in breast cancer cells and surrounding stromal cells may have a significant influence in 
breast tumour pathogenesis. 
Aromatase is expressed in a tissue-specific manner. This enzyme is mainly expressed in 
the ovaries and placenta of premenopausal women. In postmenopausal women, adipose 
tissue and skin are the major sources of oestrogen production. However, the aromatase 
activity in these tissues is significantly lower than that in the ovaries of premenopausal 
women, and the level of circulating oestrogen is much lower in postmenopausal women 
as compared to premenopausal women.  
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The expression of aromatase in breast cancer cells is up regulated as compared to that of 
surrounding non cancerous tissue (James et al., 1987). Aromatase is expressed at a higher 
level both at mRNA and protein level in the breast cancer cells as compared to normal 
breast tissue (Esteban et al., 1992; Santen R J., 1994). The expression of aromatase in 
breast cancer tissue has been demonstrated by enzyme activity measurement (Miller et 
al., 1987), immunocytochemistry (Sasano et al., 1994; Lu et al., 1996) and RT-PCR 
analysis (Zhou et al., 1996; Harada et al., 1997). Cell culture (Santner et al., 1993) and 
nude mouse experiments (Yue et al., 1994) using aromatase transfected MCF-7 cells has 
shown that aromatase expressed in breast cancer cells play a significant role in the growth 
of the breast cancer. Aromatase can stimulate breast tumour growth in both an autocrine 
and a paracrine manner (Sun et al., 1997) 
The human aromatase gene was mapped to chromosome 15, band q21 by in situ 
hybridization studies (Chen et al., 1988) and confirmed by human genome analysis 
(Sebastian et al., 2001). Human aromatase expression is regulated by a complex 
mechanism, in that seven promoters (I.1, I.2, I.3, I.4, I.5, I.6, and PII) have been identified 
and found to be utilized in a tissue-selective manner. It has been shown that various exon 
I-containing RNA messages are present at different levels in different aromatase 
expressing tissues. It is thought that aromatase expression is driven by the promoters 
situated upstream from these exon Is, providing tissue-specific control of aromatase 
expression. Increased expression of aromatase in breast tumour is due to changes in the 
transcriptional control of aromatase expression. It is known that in normal mammary 
adipose tissue aromatase is expressed through the use of promoter 1.4 (Mahendroo et al., 
1993; Zhao et al., 1995) and in tumour tissue through the use promoter ІІ (Zhou et al., 
1996) and promoter I.3 (Agarwal et al., 1996; Zhou et al., 1996). It has been suggested 
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that there is a switch in the regulatory mechanism of aromatase expression from normal 
breast tissue to cancer tissue. In normal mammary tissue, the function of promoters I.3 
and II is suppressed through the binding of EAR-2, COUP-TFI, and RARγ to S1 (Yang et 
al.,  1998 ; Yang et al.,  2002), and Snail/Slug proteins to CREaro (Figure 1.8).  
In cancer tissue, it has been shown that when the expression level of EAR-2, EARγ, Snail, 
and Slug decreases, the expression of aromatase is up-regulated through the binding of 
CREB1 to CREaro and that of ERRα to S1 (Figure 1.8). ERRα is expressed at higher 
level in the breast cancer tissue and is thought to be a positive regulatory factor that up-
regulates promoter I.3 and II (Yang et al., 1998 ). Through the binding to ERα, E2 up-
regulates the expression of MTA3 which suppresses the activity of Snail/Slug (Fujita et 
al.,  2003 ). These two zinc-finger proteins have been shown to down-regulate the activity 
of promoter 1.3. By suppressing the expression of Snail/Slug through MTA3, E2/ERα 
indirectly enhances the activity of promoter 1.3. On the other hand, E2/ERα can up-
regulate PKC-δ/MAP kinase and promoter I.1 of the aromatase gene through cross-talk 
with ErbB1/ErbB2 (Figure 1.9). Furthermore Gotzmann demonstrated that ERα's and 
Snail's function can be modulated by the PI3 kinase/Akt pathway (Gotzmann et al., 
2002). Therefore, the ligands of ERα and ERRα, e.g., phytoestrogens, can regulate 
aromatase expression. This similar positive and negative regulatory mechanism to explain 
the interaction between SF-1 and COUP-TFI with S1 was demonstrated in uterine 
endometrial cells (Zeitoun et al., 1999). A silencer element (S1) situated between 
promoters I.3 and II acts as a negative regulatory element which down-regulates the 
action of these promoters  (Zhou et al., 1998). S1 behaves as an enhancer when ERRα-1 
binds and as a repressor when COUP-TF, EAR-2 or RARγ binds (Yang et al., 1998 ; 
Yang et al., 2002). 
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Figure 1.7: Proposed mechanism of the regulation of aromatase activity in 
normal breast and cancer tissue in relation to CREB and their promoters 
(Adapted from Chen et al., 2001) 
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Snail acts as a repressor that down-regulates the expression of aromatase in normal breast 
tissue by suppressing the function of promoter I.3. A reduction of the expression of Snail/ 
Slug protein in breast cancer tissue further suggests a cancer-protective role for this 
protein in normal breast tissue (Chen et al., 2002). In normal breast epithelial cells and 
stromal fibroblasts, Snail and Slug are expressed and prevents activators from binding to 
CREaro. This results in a suppression of promoter I.3 activity. On the other hand, in 
cancer tissue, human aromatase promoter usage switches to promoter I.3 (Zhou et al., 
1996), which in response to cAMP activation of CRE binding proteins such as CREB1 
decreases the Snail and Slug expression (Figure 1.10).This reveal that cAMP plays a 
critical role in upregulating the activity of promoters I.3 and II, leading to an increase of 
the expression of aromatase/oestrogen biosynthesis in breast cancer tissue. Several factors 
may be involved in increasing the level of cAMP in breast cancer tissue. For example, 
Zhao et al. suggested that prostaglandin PGE2 synthesized in breast cancer cells induces 
cAMP response (Zhao et al., 1996). It has also been demonstrated that COX2 inhibitor 
reduces the aromatase expression by suppressing prostaglandin formation. Furthermore, 
oestrogen is capable of increasing cAMP production in breast cancer cells by stimulating 
adenylate cyclase (Aronica et al., 1994). All these observations suggest a paracrine loop 
between cAMP synthesis in breast cancer tissue and oestrogen synthesis by aromatase 
enzyme. Hence suppression of in situ oestrogen biosynthesis can be achieved by the 
prevention of aromatase expression in breast tumours or by the inhibition of aromatase 
activity.  
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Figure 1.8: Schematic Diagram showing a complex mechanism to modulate 
aromatase expression in human breast cancer tissue 
(Adapted from Chen et al., 2005) 
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Figure 1.9: The nucleotide sequence of the −104/+130 bp region containing 
promoter I.3 of the human aromatase gene 
(Adapted from Zhou et al., 1999). 
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1.8.2 Role of CREB in aromatase expression in breast tissue 
It has been reported that cAMP Response Element-Binding Proteins (CREB) may act as a 
positive transcription regulator of aromatase via cAMP (CRE1 and CRE2) induced 
promoter ІІ activity in breast tumour tissue and hence increased expression of oestrogen 
in breast cancer cells (Sofi et al.,  2003). 
To date, there is very little study which has shown any direct link between CREB 
expression and breast cancer, CREB may be involved in tumour growth and metastasis 
through increased expression of aromatase. 
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1.9 Aims of this study 
The aims of this study were threefold: 
 
1. To investigate the molecular impact of CREB family of proteins on the 
aggressiveness of breast cancer cells and to investigate the expression pattern in 
cohort of breast cancer and normal background tissue in relation to tumour 
histopathological grade, stage, nodal status and the clinical outcome of the patients 
  
2. To develop ribozyme transgenes to knockdown the expression of CREB in breast 
cancer cell lines and its effect on the biological functions of the breast cancer cells  
 
3. To investigate the role of CREB on in vitro growth and invasiveness of breast 
cancer cells following knockdown of CREB. 
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CHAPTER 2 
 
MATERIALS AND METHODS 
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2.1 General Materials 
The following cell lines have been used in this study: 
Cell Lines Origin Characteristics 
MDA-MB- 231 Human Breast cancer cell line Ethnicity: Caucasian 
Gender: Female 
Age: 51 years 
Isolation date: 1973 
Morphology: epithelial cell type 
Derived from metastatic site: Pleural 
effusion 
Oestrogen receptor: Negative 
Antigen Expression: epidermal growth 
factor (EGF), transforming growth 
factor alpha (TGF alpha), 
MCF 7 Human Breast cancer cell line Ethnicity: Caucasian 
Gender: Female 
Age: 69 years 
Isolation date: 1970 
Morphology: epithelial cell type 
Derived from metastatic site: Pleural 
effusion 
Oestrogen receptor: Positive 
Her2/ ERBB2: Negative 
MDA-MB- 453 Human Breast cancer cell line Ethnicity: Caucasian 
Gender: Female 
Age: 48 years 
Isolation date: 1976 
Morphology: epithelial cell type 
Derived from metastatic site: 
Pericardial effusion 
Oestrogen receptor: Negative 
Her2/ ERBB2: Negative 
Antigen Expression: fibroblast growth 
factor (FGF) 
MRC 5 Immortalised human 
Fibroblast cell line 
Ethnicity: Caucasian 
Gender: Male 
Age: 14 weeks old foetus 
Isolation date: 1966 
Morphology: fibroblast cell type 
Derived from Human foetal lung 
 
HECV Transformed human 
umbilical vein endothelial 
cell line  
Endothelial cell type derived from 
neonatal umbilical vein 
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The above cells were obtained from the European collection of animal cell culture 
(ECACC), except HECV which was purchased from Interlab, Milan, Italy. 
 
2.1.1 Preparation of Reagents, Buffers and Standard solutions 
All the standard reagents and chemicals which were routinely used throughout this study, 
unless otherwise stated, were purchased from Sigma-Aldrich Inc., Poole, Dorset, UK.   
 
Tris- Boric acid- EDTA (TBE) Electrophoresis Buffer 
A stock solution of TBE was prepared as a 5 × concentrate. The solution was made by 
dissolving 540g Tris-Cl (Melford Laboratories Ltd., Suffolk, UK), 275g Boric acid 
(Duchefa Biochemie, Haarlem, The Netherlands) and 46.5g EDTA (Duchefa Biochemie, 
Haarlem, The Netherlands) in 10 litre dH2O. A working solution was prepared by 
dissolving 200ml of stock solution in 800ml of distilled water.  
 
DEPC water 
A stock solution was prepared by dissolving 250µl of Diethyl Pyrocarbonate (DEPC) 
(Sigma-Aldrich Inc., Poole, Dorset, UK) in 4750µl distilled water and autoclaved before 
use. 
 
Preparation of Ethidium Bromide (EtBr) Staining Solution (Strength: 10mg/ml) 
The Working solution was prepared by dissolving 100mg Ethidium Bromide (Sigma-
Aldrich Inc., Poole, Dorset, UK) in 10ml of distilled water. The solution is mixed well to 
dissolve powder and wrapped in aluminium foil.  
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Preparation of Complete Cell Culture Medium 
This solution was prepared by mixing 50ml of heat inactivated Foetal calf serum (FCS) 
(PAA Laboratories, Austria) in 500ml DMEM/F12 (PAA Laboratories, Austria) with 
2mM L- glutamine. To this 250µl of Benzyl penicillin (100 units/ml, Britannia 
Pharmaceuticals Ltd., UK) and 200µl of Streptomycin (100µg/ml, Gibo BRC, Paisley, 
Scotland) was added and the solution was then stored up to a month at 4ºC. 
 
Preparation of G418 Selection Media 
• 250µl of G418 (200mg/ml) 
• 500ml of complete cell culture medium 
• Wrap in aluminium foil to protect from light and stored at 4ºC. 
 
Balanced Salt Solution (BSS) 
A 5 litre stock solution of 1XBSS (137mM NaCl, 2.6mM KCl, 1.7Mm Na2HPO4 (BDH 
Chemicals Ltd., Poole, UK) and 8mM KH2PO4) was prepared by dissolving 40g NaCl, 1g 
KCl (Fisons Scientific Equipment, Loughborough, UK), 5.72g Na2HPO4 and 1g KH2PO4 
(BDH Chemicals Ltd., Poole, UK) in dH2O. The pH was adjusted to 7.4 with 1M NaOH 
before use. 
 
Preparation of 0.05M EDTA 
A 5 litre stock solution at 1×BSS contained 137mM NaCl, 2.6Mm KCl, 1.7mM Na2HPO4 
and 8mM KH2PO4 and 0.05M EDTA (Duchefa Biochemie, Haarlem, The Netherlands). 
These were dissolved in 5 litres distilled H2O and pH adjusted to 7.4 before autoclaving.  
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Trypsin (25mg / ml) 
A stock solution of trypsin was prepared by dissolving 500mg trypsin in 20ml 0.05M 
EDTA. This solution was then filtered through a 0.2µm ministart filter (Sartorius, Epsom, 
UK) and stored at -20ºC. The working solution was prepared by further dissolving 250µl 
of trypsin solution in 10ml of 0.05 EDTA. 
 
Penicillin (120mg/ml) 
The stock solution was prepared by dissolving 600mg benzyl penicillin sodium (Britannia 
Pharmaceuticals Ltd., UK) in 5ml sterile injection water (Braun, Germany). 
 
Tris Buffered Saline (TBS) 
TBS Buffer was prepared as a 10× concentrate. A stock solution was prepared by 
dissolving 24.22g Tris-Cl (Melford Laboratories Ltd., Suffolk, UK) and 80.06 NaCl in 1 
litre of distilled water. This solution contained 200mM Tris and 1.37M of NaCl. 
 
Preparation of Antibodies 
Antibodies obtained from the manufacturers (detailed in respective chapters) are diluted 
in 0.1% Bovine serum albumin (BSA) in BSS buffer and stored in 100µl aliquots at -
20ºC. 
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Preparation of Inhibitor Buffer 
We dissolve 2.76g of sodium nitrate, 630g of sodium fluoride, 5.58g EDTA, 10g 
Na2H2PO4 and 3× 105 Units of Aprotonin. The solution is made up to 1 litre with distilled 
water, prepared as a 3× concentrate and stored at 4ºC.  
 
Preparation of Cell Lysis Buffer 
The Stock Solution was prepared by dissolving 0.24g Tris-Cl, 0.435g NaCl, 0.25g 
Sodium Deoxycholate, 0.135g Sodium Orthovanadate , 0.01g Sodium Azide, 1ml of 
Triton x-100 in 50ml of distilled water. The solution is prepared as a 2× concentrate and 
stored at 4ºC. 
A working solution is prepared by diluting 10ml of the stock solution in 6.6ml of inhibitor 
buffer, 200µl of 0.1mM PMSF (phenylmethylsulfonyl fluoride), 80µL of 10mM CaCl2, 
3ml of 10%Triton X-100 made up to 20ml with distilled water. 
 
Transfer Buffer (for Western Blot) 
A stock solution of 5 litres was prepared by dissolving 15.15g Tris, 72g Glycine and 1 
litre of methanol (Fisher Scientific, Leicestershire, UK) in dH2O. 
 
Preparation of Amino Black  
 A working solution is prepared by dissolving 10mg Napthalene black (Edward Gurr Ltd., 
Suffolk, UK) in 10ml Acetic acid (Fisher Scientific, Leicestershire, UK) and 25ml 
Ethanol (Fisher Scientific, Leicestershire, UK). This solution was made up to 100ml with 
distilled water and stored at room temperature. 
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Preparation of Fluorescamine for protein quantisation 
The working solution is prepared fresh by dissolving 3mg of Fluorescamine in 10ml of 
acetone. 
 
Preparations of Amino Black destain 
This solution is prepared by mixing 25ml ethanol and 10ml acetic acid and made up to 
100ml with distilled water. 
 
Preparation of Protein Loading Dye 
This solution is prepared as a 10× concentrate. We dissolve 0.125g Bromophenol Blue 
(Sigma-Aldrich Inc., Poole, Dorset, UK) and 20g sucrose in 50ml of distilled water and 
freeze it in microcentrifuge tubes until required.  
 
Preparation of Ponceau S 
A working solution is prepared by mixing 20ml of Ponceau S (Sigma-Aldrich Inc., Poole, 
Dorset, UK) concentrate in 180ml of distilled water and stored at room temperature. 
 
Preparation of 0.1% Comassie Blue 
The working Solution is prepared by dissolving 1g Comassie, 400ml Methanol and 100ml 
Acetic acid in distilled water. The total volume is made up to 1litre. It is then filtered and 
stored at room temperature. 
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2.2 General Methods 
2.2.1 Cell Culture and Storage 
Cell lines were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM- Sigma: pH 
7.3) containing 2mM L-glutamine, 15mM HEPES and 4.5mM NaHCO3 (a pH buffer) 
supplemented with 10% heat inactivated (55°C for 30 minutes) foetal calf serum (PAA 
Laboratories, Austria), 50units/ml Benzylpenicillin (Britannia Pharmaceuticals Ltd) and 
50µg/ml Streptomycin (Gibco BRC, Paisley). Foetal calf serum contains the necessary 
serum growth factors. All cell lines were grown in either 25cm² or 75cm² tissue culture 
flasks (Greiner Labortechnik, Germany) in monolayers depending on the application. 
Culture flasks were loosely capped, to allow gaseous exchange and then placed 
horizontally in a humidified incubator (98% humidification achieved with water tray in 
the incubator) (Sanyo Electric, Japan) at 37ºC with 5% CO2 (act as a buffer with the 
NaHCO3) in air. The culture flasks were then left until sub-confluent (2-3 days) for 
experimental work or until fully confluent (7 days) for subculture. 
 
2.2.2 Trypsinization and Counting of cell lines 
• All procedures were carried out under sterile condition using class ІІ hoods and 
autoclaved instruments to prevent any potential contamination. 
• Tissue culture flask was taken out from incubator and the medium aspirated. 
• Following this the flasks were rinsed with 5ml of EDTA in Hanks Balanced Salt 
Solution (HBSS containing 137mM NaCl, 8mM Na2HPO4, 3mM KCl and 
1.5mM KH2PO4) buffer to remove traces of serum which would inhibit the 
enzymatic action of trypsin. 
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• After this 1-2 ml of trypsin / EDTA solution (Trypsin0.01% (w/v) and EDTA 
0.05% (w/v) in HBSS buffer) was added to the flask and was incubated for 5 
minutes at 37ºC to allow cell detachment. Following this 5ml of DMEM was 
added to the flask to neutralised trypsin and transferred to the universal container. 
• The cells were centrifuged at 1500g for 5 minutes and medium aspirated.  
• Following this the pellets were re-suspended in 5mls of DMEM solution and cells 
were  re-cultured in tissue flasks, counted for immediate experimental work or 
stored by freezing in liquid nitrogen. 
• Cell counts were performed using Neubauer haemocytometer counting chamber 
with an inverted microscope (Reichert, Austria) at ×10 magnification. 
 
2.2.3 Storage of cell lines 
The cell lines were stored in liquid nitrogen by re-suspending at a cell density of 1×106 
cells/ml in complete medium (DMEM) containing 10% dimethylsulphoxide (DMSO; 
Fisons, UK). 1ml of cell suspension was transferred into pre-chilled cryopreserve vial and 
then frozen at -80ºC for 1 day before storage in liquid nitrogen (-196ºC).  
 
2.2.4 Resuscitation of cell lines  
To thaw cells, the cryo-vial was removed from liquid nitrogen and was allowed to thaw 
rapidly in a 37ºC water bath. The cell suspension was transferred to a universal container 
containing 2ml of pre-warmed DMEM and incubated at 37ºC for 10 minutes. The cell 
suspension was then centrifuged at 1600 rpm for 5 minutes and the supernatant discarded. 
The cell pellet was re-suspended in 5ml of DMEM and washed twice to remove any 
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possible trace of DMSO.  The cell pellet was then re-suspended in 5ml of DMEM and 
transferred to a 25cm² tissue culture flasks. The cells were incubated at 37ºC with 98% 
humidification and 5% CO2 in air.  
 
2.3 Isolation of total RNA from cells using the guanidine thiocyanate method 
Reagents Required:  
• RNA isolation reagent 
• Chloroform 
• Isopropanol 
• 75% Ethanol 
• DEPC treated water 
 
Ribonucleic acid (RNA) is present within the nucleus, cytoplasm and mitochondria of all 
living eukaryotic cells. There are three main subtypes of RNA which are classified as 
ribosomal RNA (rRNA), transfer RNA (tRNA) and messenger RNA (mRNA). mRNA is 
of particular importance as it carries the genetic information for subsequent protein 
synthesis. The presence of specific mRNA therefore gives a good indication of which 
proteins are being produced by the cell at any one time. 
RNA is susceptible to degradation by RNase and hence special precautions are taken to 
minimise this during isolation. All methods involving RNA isolation rely on the use of 
strong denaturants to inhibit the action of endogenous RNase.  Guanidine, thiocyanate 
and chlorine are amongst the most effective protein denaturants and inhibitors of 
ribonucleases. 
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RNA isolation using the guanidine thiocyanate method was first described by 
Chomczynski and Sachhi in 1987. This procedure involves combining of acid guanidine 
thiocyanate, phenol and chloroform in a single step RNA extraction. RNA is prone to 
degradation by RNase and hence this method relies on use of strong denaturants like 
guanidine and thiocyanate to inhibit the action of endogenous RNase. The reaction is set 
under acidic conditions, so that the DNA is selectively partitioned into the organic phase 
whilst the RNA remains in the aqueous phase. Cells of approximately 80- 90% 
confluence were harvested from the tissue culture flask using a cell scraper and lysed in 
1ml of RNA isolation reagent (Advanced Biotechnologies Ltd, Surrey, UK) by repetitive 
pipetting. The resultant homogenates were transferred to microcentrifuge tubes (Fisher 
Scientific, UK) and placed on ice for 5 minutes to allow the complete dissociation of 
nucleoprotein complexes. 200µl of chloroform per ml of RNA isolation reagent was 
added to the homogenate followed by vigorous shaking for 10-15 seconds. The samples 
were then incubated on ice for 10 minutes and centrifuged (Biofuge13, Heraeus, 
Sepatech) at 15000rpm for 10 minutes at 4ºC. Following centrifugation the homogenate 
gets separated into two distinct phases: the lower organic phase of DNA and protein and 
the upper aqueous phase of RNA. The aqueous phase containing RNA (40- 50% of total 
volume of homogenate) was transferred to a fresh tube and 500µl of isopropanolol 
(Sigma-Aldrich Inc., Poole, Dorset, UK) was added to precipitate RNA. Samples were 
then placed on ice for 10 minutes and centrifuged at 12000 rpm for 10 minutes at 4ºC. 
Following this the supernatant was removed and the resultant RNA pellets were mixed 
with 1ml of 75% ethanol by vortexing. The RNA pellets were precipitated by 
centrifugation at 12000 rpm for 5 minutes at 4ºC, briefly dried at 55ºC for 5 minutes in 
order to evaporate the remaining ethanol and then treated with 50µl DEPC (Diethyl 
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pyrocarbonate, Sigma) water by vortexing for 1 minute. RNA concentration was 
determined by measuring its absorbance at wavelength of A260nm/A280nm (WPA UV 
1101, Biotech Photometer). A260nm/A280nm ratio gives an estimate of the purity of the 
RNA. Pure RNA solutions have an optical density ratio of 2.0. Optical density values less 
than 1.5 indicates ethanol or protein contamination. The RNA sample then was stored at -
80ºC for future use. 
 
2.4 Reverse Transcription- Polymerase Chain Reaction (RT-PCR) 
Reverse transcription leads to synthesis of complementary cDNA from RNA. It is 
followed by polymerase chain reaction (PCR) and the two processes together are known 
as RT- PCR. RT-PCR is a sensitive and highly versatile technique that has greatly 
enhanced the study of genes and how they are controlled.  RT- PCR is a more sensitive 
technique for the analysis of mRNA as compared to other techniques like Northern blots 
and RNA dot blots. This technique requires a small amount of RNA and is more sensitive 
and rapid in detecting genetic sequences as compared to other procedures. In this study 
RT- PCR was performed using a Dura Script RT-PCR Kit (Sigma-Aldrich Inc., Poole, 
Dorset, UK)) according to manufacturer’s instructions. The following components were 
mixed together in a polypropylene tube (Appendoff):  
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Reagent Volume Concentration 
RNA template Depends on RNA 
concentration 
× 
PCR water Depends on RNA 
concentration 
× 
Deoxynucleotide 1µl 500µM each dNTP 
Anchored oligo dT 1µl 0.5µg/µl 
Reverse Transcriptase  1µl 1 unit/µl 
RNase inhibitor 1µl 1 unit/µl 
PCR buffer 2µl 5×concentrate 
Total Volume 20µl × 
 
The reaction mixture was incubated at 47ºC for 1hr to commence cDNA synthesis 
followed by incubation at 75ºC for 10 minutes to inactivate RNase. The cDNA was 
diluted to 1:2 in PCR water (distilled, deionised and UV- treated H2O) and the samples 
were either stored at -20ºC until required or used for PCR amplification.  
 
2.5 Polymerase chain reaction (PCR) 
Polymerase Chain Reaction, invented by Karey Mullis in 1983 is a simple technique of 
amplifying DNA to produce a desire amount from a single target DNA molecule.  
Principle:  
• It relies on the principle of a chain reaction in which each target molecule is 
subject to further amplification. 
• It requires two short DNA sequences (oligonucleotides- Forward and Reverse 
primers) which binds by base pairing and are complementary to a defined 
sequence on each of the two strands of the DNA. These primers are aligned with 
the 3’ ends directed towards each other. 
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• It involves the use of heat-stable DNA polymerase (Taq polymerase, a 
thermostable enzyme from Thermus aquaticus bacteria which is native to hot 
springs). The use of this enzyme means that fresh polymerase does not need to be 
added after each denaturation step as the bacteria survives temperature over 95ºC. 
•  It involves cycles of denaturation (96ºC) of template, annealing (50ºC) of primers 
and extension (72ºC) by DNA polymerase (Figure: 2.1) for amplification. The 
whole reaction is performed using a PCR thermal cycler (Gene Amp 9700, Perkin 
Elmer) which is a programmable machine that can rapidly change temperature and 
can incorporate upto 96 reactions simultaneously. 
Amplification of cDNA templates previously prepared was performed using PCR. The 
following method was used for cDNA amplification in this study. All reactions were 
performed to a total volume of 20µl, with 10µl of MastermixTM (0.625 U of Taq DNA 
polymerase from Thermus aquaticus, 75mM Tris- HCL (pH 8.8 at 25°C), 20Mm 
(NH4)2SO4, 1.5mM MgCl2, 0.01% (v/v) Tween20, 0.2 mM from each of the following: 
dATP, dCTP, dGTP, and dTTP (ABgene , Surrey, UK), 1µl of cDNA template, 1µl of 
each forward and reverse primer and 7µl of PCR water in a thin walled PCR tube. PCR 
reactions were performed using a PCR thermal cycler as mentioned above. PCR 
conditions were variable depending on the application and consisted of 35-40 cycles. 
The PCR product is then analyzed on an agarose gel and is detected with ethidium 
bromide staining. 
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Figure 2.1: Different steps in PCR 
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2.6 Agarose gel electrophoresis 
The resultant DNA PCR products were separated using horizontal gel electrophoresis 
apparatus (Gibco BRL, Life Technologies) at either 0.8% or 2% depending on the PCR 
product. A low percentage agarose gel (0.8%) is used to separate PCR products with a 
high number of base pairs (>500bp) and 2% agarose gel to separate DNA fragments with 
low number of base pair (<500bp).  
Procedure: 
20mls of agarose gel solution which was prepared by dissolving 0.8g or 2g of agarose 
(depending on the size of PCR product) in 100ml of TBE (Tris Borate Electrophoresis) 
buffer (0.45M Tris-HCl, 0.44M Borate, 12.5mM EDTA). The solution was then boiled at 
100C until the agarose had completely dissolved (when the solution had become clear). 
The agarose gel solution of appropriate concentration was poured into a universal 
container and cooled down before casting it into the mould in the electrophoresis 
apparatus. Following this a comb was inserted into the liquid gel to create wells. The gel 
was then allowed to set at room temperature for about 30 minutes. Once the gel had set, 
TBE buffer was added into the electrophoresis apparatus upto a level of about 5mm above 
the surface of the gel and the comb was removed from the gel, leaving a row of wells. A 
1kb pair ladder (Pharmacia Biotech, USA), prepared according to the manufacturer's 
instructions in a loading buffer (Glycerol, Bromophenol blue), and PCR products were 
loaded into separate wells of the gel (5µl per well). The gel was then run at a constant 
voltage of 100 volts (Gibco BRL Power pack model 250EX, Life Technologies) and was 
continued for 35-55 minutes or until the samples had migrated about two thirds down the 
agarose gel (depending on the PCR product size). The DNA PCR product was then 
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stained using ethidium bromide solution for 5 min with continuous agitation to provide 
uniform staining. Ethidium bromide is a dye that binds to double stranded DNA by 
interpolation between the base pairs and fluoresces when exposed to the UV light. This 
was sometime followed by destaining in tap water for 30-60 minutes if necessary for 
removal of background staining on the agarose gel from the fluorescent dye. PCR DNA 
products were then visualised using an Ultra Violet Transilluminator (UVP, Cambridge, 
UK) and photographed using a thermal printer or scanned for storing images 
electronically. 
 
2.7 Real time quantitative Polymerase Chain Reaction (QPCR) 
Over the last two decades PCR has become an essential part of most laboratories involved 
in biomedical research. The development of real-time QPCR added a new dimension to 
PCR and a significant improvement in the quantification of nucleic acid samples. Real-
time quantitative polymerase chain reaction (QPCR) is a new technology, developed in 
1992 which allows quantification of DNA, cDNA, or RNA templates as the products 
accumulates with each cycle of amplification. It provides a broad dynamic range for 
detecting specific gene sequences with excellent sensitivity and specificity. It is based on 
the detection of a fluorescent reporter molecule that increases as PCR product 
accumulates with each cycle of amplification (the level of fluorescence detected is 
directly proportional to the PCR product yield). The level of fluorescence is continuously 
monitored on a computer screen and hence the term ‘real-time’. Fluorescent reporter 
molecules include dyes that bind double-stranded DNA (i.e. SYBR® Green I) or 
sequence–specific probes (i.e. Molecular Beacons®, Amplifluor® probes, Scorpions® 
probes or TaqMan® Probes).  
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There are two basic types of QPCR which includes SYBR® Green I based quantitative 
PCR and probe based quantitative PCR. The first method uses SYBR Green I fluorescent 
DNA binding dye, which binds to all double–stranded DNA and detection, is monitored 
by measuring the increase in fluorescence throughout the cycle. This dye binds non-
specifically and hence can binds to the contaminated products that are amplified during 
PCR as well.  The second method which is a newer improved version of QPCR uses 
sequence–specific probes. These are oligonucleotide sequences which contains a 
fluroscopically- labelled base known as fluorophore and a quencher. Prior to PCR, the 
fluorophore and the quencher lie next to each other, so that there is no fluorescence. 
However during the annealing stage the fluorophore and quencher get separated as the 
oligonucleotide probe becomes incorporated into the PCR product and results in an 
increase in fluorescence. These probes are specific for the desired PCR product and hence 
any contaminants in the reaction which are amplified will not fluoresce.   
The iCycler iQTM system (Bio-Rad, Camberley, UK) was used throughout this project and 
consists of a 96-well thermal cycler module connected to a laser and charge-coupled 
device (CCD) optics system. It consists of two key components, namely an excitation 
system and a detection system. The excitation system consist of a cooler fan, a tungsten 
halogen lamp, an infrared absorbing heat filter, a filter wheel that is fitted with optical 
filters, and a dual mirror arrangement that allows simultaneous illumination of all the 
reaction wells. The laser light is directed through the filter and a pre- selected colour 
optical filter to excite the fluorescent molecules that have become unquenched in the PCR 
solution in each reaction well. Emissions are then sent to the CCD camera (detection 
system). The primary components of the detection system include an emission filter 
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wheel, an image intensifier and a cooled detection camera. Fluorescent light emitted from 
each well passes through both the emission filter and intensifier, which increases the 
fluorescence prior to detection by the camera where they are analysed by the software’s 
algorithms. Collected data are subsequently sent to the computer. Emissions are measured 
constantly. During the initial cycles of QPCR there is very little change in fluorescence 
from the initial level as the products accumulate exponentially. After further cycles, the 
number of products rapidly increases and reaches the exponential phase of PCR and then 
plateau again as the substrates are progressively consumed.    
There are four types of probe systems available which are as follows: Molecular 
Beacons®, Amplifluor® probes, Scorpions® probes or TaqMan® Probes).  
 
2.7.1 TaqMan® probe based assay 
The TaqMan® assay is a sensitive method to determine the presence or absence of 
specific target sequences. TaqMan® probes are used to detect the presence and quantify 
the amount of specific target sequences by employing the 5'→3' exonuclease activity of 
Taq polymerase. These Probes are designed to anneal to the target sequence between the 
forward and reverse primers.  The probe consists of oligonucleotide sequence which is 
labelled at the 5' end with a reporter fluorochrome (6-carboxyfluorescein [6-FAM]) and a 
quencher fluorochrome (6-carboxy-tetramethyl-rhodamine) at the 3' end. These probes  
 
have a higher Tm (Melting Temperature) than the primers, and during the extension phase 
must be 100% hybridized for success of the assay. The close proximity of the quencher to 
the reporter fluorochrome prevents its natural fluorescence. However, as the PCR 
progresses the probe binds to the PCR products and Taq polymerase cleaves the reporter 
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fluorochrome and the quencher from the probe, releasing the sequence specific 
fluorescent signal (reporter fluorochrome). The amount of fluorescence released during 
the amplification cycle is proportional to the amount of PCR product generated in each 
cycle. 
 
2.7.2 Amplifluor® probe based assay 
Nazarenko first described the Amplifluor based Q-PCR in 1997 (Nazarenko et al., 1997). 
The principle is based on energy transfer from an excited fluorophore to the acceptor 
moiety which results in quenching of the fluorescence.  This quenching is accomplished 
by linking the fluorophore and the acceptor to an oligonucleotide primer. This system 
requires three oligonucleotides which are as follows: A target specific forward primer, a 
target specific reverse Z primer which incorporates a unique Z sequence at the 5’ end of 
the primer and a universal primer labelled with fluorescein (FAM) which also contains a 
Z sequence attached at the 3’end. Amplifluors® combine primer and probe in one 
molecule. The Amplifluor® Probe and the forward primer are used in a 10-fold excess 
over the reverse primer to ensure high yield of the fluorescent product.  As the reaction 
commence, the forward primer attaches to the target cDNA and begins extending. The 
reverse primer, which is specific to the target DNA, also extends in the opposite direction. 
Since the latter has a Z sequence attached, when the forward primer attaches to this newly 
synthesised sequence, it also synthesises an oligonucleotide containing a complementary 
Z sequence. After few cycles, the reverse primer/Z sequence is depleted, leaving only the 
forward primer and the probe. At this point, the Z sequence of the probe attaches to the  
newly synthesised Z sequence. When the forward primer extends to the probe and 
beyond, it results in a conformational change of the probe, separating the quencher and 
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fluorophore. This results in an increase in fluorescence. The fluorescent signal produced 
during each PCR cycle directly correlates to the amount of amplified DNA generated.  
 
2.7.3 Molecular Beacons probe assay 
Molecular Beacons probes belong to a special class of dual-labelled probes having self-
complementary ends that form a stem-loop structure (hairpin) in their native state. It 
contains a reporter dye (fluorophore) at the 5’free end of the hairpin and a quencher at the 
3’ free end. In their native state, the reporter dye and quencher lie close to each other, 
preventing fluorescence. Once the reaction proceeds the oligonucleotide anneals to the 
developing PCR product sequence and the probe undergoes a spontaneous conformational 
change that results in separation of the fluorophore and quencher  from each other, 
leading to the production of fluorescence. As PCR progresses, the number of amplicons 
(PCR products) increase and the number of probes that bind to the products also increase, 
hence an increase in fluorescence intensity. 
 
2.7.4 Scorpions probes based assay 
Scorpions probes based assay is a valuable tool for Rapid, Real-time qPCR and Gene 
Quantification. Scorpions probes are bi- functional molecules which incorporate two 
distinct structures: 1) a target-specific DNA probing sequence and 2) a target-specific 
PCR primer. These probes are based on a uni- molecular mechanism unlike TaqMan® 
probes and Molecular Beacons which are based on a bi-molecular probing mechanism  
and hence does not require enzymatic cleavage of the probe during PCR cycling. This 
structural arrangement provides a number of important advantages over other PCR probe 
formats: 
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• Simplified Assay Design 
• Enhanced Sensitivity and Specificity 
• Measurably Faster Reactions 
Furthermore, they combine primer and probe in one molecule, with the primer at the 3' 
end and the probe contained within a hairpin-loop structure at the 5' end. The molecules 
also contain a fluorophore. Scorpions probes, unlike other probes, are designed in such a 
way that they emit light only when bound to their complementary target sequence during 
PCR amplification. In the quiescent state, the fluorophore and quencher lie next to each 
other, hence no fluorescence. As the reaction progresses, the scorpion primers is extended 
on the target DNA sequence. During the annealing phase, the scorpions molecule 
undergoes a conformational change, so that the probe containing the fluorophore bends 
over to anneal with the corresponding sequence on the target DNA. Since the 
oligonucleotide /quencher is now free, fluorescence is produced.   
 
2.8 Western Blotting 
2.8.1 Preparation of protein from cell lysates 
To extract proteins, cell lines were grown as monolayers in 25cm2 or 80cm2 culture 
flasks until 90% confluent is achieved. The cells were extracted using a disposable cell 
scraper. The cells were then transferred, using a pipette to a universal container and 
centrifuged at 1600 rpm for 5 min. The supernatant was discarded and cell pellet  
resuspended in 200 µl of cell lysis buffer (10mM NA3VO4, 0.5% SDS, 0.5% Triton X-
100m, 2mM CaCl2, 100µg/ml (1mM) phenylmethylsulfonyl fluoride, 1mg/ml (10U/ml) 
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aprotinin, 1mg/ml leupeptin and 0.1% IGEPAL CA-630) and the resultant lysates 
transferred into 1ml microcentrifuge tubes. The samples were then rotated on a rotating 
wheel for 40 min to ensure appropriate lysis and extract protein from the cell lysate. The 
tubes were centrifuged (Biofuge 13 Heraeus, Sepatech) at 13,000 rpm for 10 minutes to 
remove cellular debris and collect the protein. The supernatant was transferred to a clean 
Appendoff tubes and stored at -20ºC until ready to use for SDS-PAGE.  
The protein concentrations were adjusted to a working range of 1-2mg/ml by the addition 
of sample buffer (10% glycerol; 5% 2-mercaptoethanol; 3% SDS; 80mM Tris-HCl (pH 
6.8); 0.012% bromophenol blue) for crude cell lysate analysis. The crude cell lysate 
samples were then denatured under reducing conditions by boiling at 100°C for 5 
minutes. The samples were, stored at -20°C  
 
2.8.2 Determination of cellular protein concentration 
Equal amounts of protein from each sample were used to determine the total cellular 
protein concentration and to detect the differences in protein levels in cells following 
various treatments.   
The method employed to measure cell lysate protein concentrations was modified from 
the method described by Bohlen (Bohlen et al., 1973) using the reagent 4-phenylspiro 
[furan-2(3H), 1'-phthalan]-3, 3'- dione (fluorescamine). Fluorescamine reacts with protein  
amino groups to yield a highly fluorescent product at an alkaline pH and this product can 
be detected using a fluorescent plate reader as described below: 
40µl of protein from each lysate sample and 40µl of bovine serum albumin [100mg/ml, 
diluted in a cell lysis buffer to give a working concentration range between 0.50-
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0.79mg/ml] was mixed in a 96 well microtitre plate. 60µl of sodium phosphate buffer was 
then added to each well and the pH adjusted to 8.8 using 1M Sodium Hydroxide. In 
addition, 25µl of fluorescamine (Sigma) solution (working concentration of 0.3mg/ml 
achieved by dissolving in acetone) was added to each well. The plate was then placed into 
a fluorescence plate reader (Denly, UK) and the fluorescence measured at an excitation 
wavelength of 540nm and emission wavelength of 590nm. A standard protein curve was 
then constructed from the bovine serum albumin and the protein concentrations from the 
cell samples were determined accordingly.  
 
2.8.3 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS-PAGE) 
In this method equal volumes of samples and the protein standard (Ladder) were loaded 
into the wells of the polyacrylamide gel. A high voltage current (Bio Rad power pac 300) 
was then applied (30mA at 180V) which causes the protein samples to migrate towards 
positively charged anode. The SDS binds to protein and the resultant protein –SDS 
complex is then separated on the basis of their molecular mass. The protein size was then 
determined by comparing the gel mobility of a particular band with that of the ladder. 
Following electrophoresis bands were then visualised using Coomassie Blue or the 
proteins are electroblotted onto the nitrocellulose membrane. 
 
2.8.4 SDS- PAGE Gel Preparation 
SDS- PAGE was carried out by assembling the gel (Mini Protean 11 gel system) 
apparatus according to the manufacturer’s instructions (Bio- Rad Laboratories, Richmond 
Ca, USA). Polyacrylamide gel is prepared by polymerising acrylamide with a cross- 
linking agent (methylene- bis- acrylamide) in the presence of a catalyst (TEMED 
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N,N,N,N-tetramehylethylenediamine) and the initiator (ammonium persulphate). The 
pore size is determined by the relative proportion of the acrylamide to the cross-linking 
agent and the rate at which the gel set is controlled by varying the concentrations of 
persulphate and TEMED within the acrylamide mixture. The ingredients used in 
preparing 8% or 10% resolving and stacking gel are shown below. 
A brief description of the procedure is shown below: The resolving gel prepared was 
transferred to the gel system until the gel is 0.5 cm from the lower end of the gel plate. 
Following this 0.1% SDS solution was added to form a layer on the top of the gel 
solution. This is to ensure that the gel set with the smooth surface. The gel was then 
allowed to set at the room temperature for about 40 minutes. Once the gel is set the SDS 
solution is removed and the gel washed with distilled water. The stacking gel was then 
added to the gel system till it reaches the top end of the gel plate. A well forming comb 
was then inserted between the glass plates till it reaches the top of the resolving gel and 
allowed to set at room temperature. The well forming comb was removed and the gel 
cassette assembled in the electrophoresis tank as per manufacturers guide (Bio Rad 
Laboratories, USA). The tank was then filled with the running buffer. The protein 
samples (mixed with the loading buffer) and the standard protein were loaded into the 
wells. The tank was then connected to the power pack at a constant current of 15mA 
Electrophoresis was then continued till the bromophenol blue in the loading buffer reach 
the bottom of the gel. Following this the gel was removed and washed in the transfer 
buffer to remove the electrophoresis buffer, detergents and salts.  
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Preparation of SDS-PAGE Gel 
 
        Strengths (mls) 
 
       Strengths (mls) 
 
Resolving gel composition 
              (10mls) 
             10%                  8% 
Distilled Water               4.0                        4.6 
30%Acrylamide/          
0.8% Bisacrylamide 
               
              3.3 
                  
                 2.7 
1.5M Tris (pH = 8.8)                2.5                  2.5 
10% SDS               0.1                  0.1 
10% APS                0.1                  0.1 
TEMED               0.004                  0.006 
 
                   Strengths (mls)             Stacking gel composition 
                          (2mls) 
                           5% 
                   Distilled Water                            1.4 
                  30%Acrylamide/           
                  0.8% Bisacrylamide 
                            
                           0.33 
                  1.0M Tris (pH = 6.8)                            0.25 
                  10% SDS                            0.02 
                  10%APS                            0.02 
                  TEMED                            0.002 
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2.8.5 Electroblotting 
After gel electrophoresis proteins were transferred to nitrocellulose membrane where the 
proteins are detected by specific monoclonal or polyclonal antibody against them. A 
nitrocellulose membrane (Amersham International Plc) and filter paper (Whatman, Kent, 
UK) were cut to the dimension of the gel (6 x 9cm) and immersed in transfer buffer for 
10-15 minutes. Two wet filter paper were placed over the cathode and nitrocellulose 
membrane along with the gel was placed on top of this which was then covered with two 
further pieces of pre soaked filter paper forming a sandwich. The surface of this sandwich 
was flattened out to avoid the formation of any air bubbles that might interfere with 
protein transfer. The positive electrode (anode) was placed on top of this and a constant 
current 5 Volts, 500mA and 8 Watts was applied for 40 minutes to facilitate protein 
transfer from gel to the nitrocellulose membrane. 
Following this, the nitrocellulose membrane was removed and immersed in ponceau S 
solution for one minute at room temperature. Ponceau S stains proteins on nitrocellulose 
membranes and excess staining was removed by rinsing the membranes in distilled water 
until the bands were visible. The position of the molecular weight markers were then 
indicated on the membranes using a pencil. Following Ponceau S staining the 
nitrocellulose membranes were transferred to 50ml polypropylene tubes and incubated in 
15ml of blocking buffer (10% milk solutions in TBS) for 40 – 60 minutes to block non-
specific protein binding of the antibody. The blocking buffer was then removed and 5ml 
of 3 % milk solution in TBS and 0.1% Tween 20 containing the relevant primary 
antibodies in the appropriate concentrations was added. This was then incubated with 
agitation for 60 minutes at room temperature which facilitates an even distribution of 
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antibody on the membrane. Excess primary antibody was removed by washing the 
membranes three times, for 10 minutes per wash, using 10ml of wash buffer. The 
membranes were then incubated with 5ml of secondary horseradish peroxidase -
conjugated antibody (prepared in a similar manner to that of the primary antibodies) at 
room temperature on a rotating wheel for 60 minutes. Unbound secondary antibody was 
removed by washing the membranes in the similar manner described for the primary 
antibody. The membranes were then washed twice in 10ml of 0.2% TTBS buffer (Tween 
20 Tris Buffered Solution) for 15 minutes each.  Finally the membranes were washed 
with 10ml of TSB buffer only to remove any residual detergent and transferred to 
weighing boats until ready for chemiluminescent detection. 
 
2.8.6 Detection of protein using chemiluminescence  
In this Horse Radish Peroxidase (HRP), in the presence of hydrogen peroxide (H2O2) 
oxidises the chemiluminescent substrate luminal, with concomitant production of light 
which is detected by exposing the nitrocellulose membrane to a photographic film. The 
intensity of light emission is increased 1000 fold in the presence of phenol (chemical 
enhancer). 8ml of KPL chemiluminescent reagent A and 8ml of KPL chemiluminescent 
reagent B were mixed together in a universal container and poured into a weighing boat. 
The nitrocellulose membrane was then placed over the tissue paper to drain the excess 
buffer. Following this the membrane was immersed in the chemiluminescent solution for 
60 seconds and excess solution removed as before by using tissue paper. The 
chemiluminescent treated membrane was then wrapped in Saranwrap™ and placed in an 
autoradiography film cassette. In the dark room, using safe lighting condition a piece of 
autoradiography film (Kodak XOMAT-AR) was placed over the nitrocellulose membrane 
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and the cassette closed. The membrane was then exposed to X-ray film for 60 seconds for 
the best possible resolution of the antibody signal and the film developed using an 
automated film developer (X-ograph Imaging Systems, Malmesbury, Wiltshire, UK). 
After developing the film, the membrane was removed from the cassette and stained in 
Amido black stain for 15 seconds. The Amido black stain provides a permanent record of 
the protein positions on the membrane. The membranes were then placed in an Amido 
black de-stain solution until the protein bands are seen on the membrane.  
 
2.9 Immunohistochemical staining  
Immunohistochemical staining was carried out using frozen sections of breast tumour and 
normal mammary tissue cut at a thickness of 6µm using a cryostat. The fixed tissue 
sections were mounted on Super Frost Plus microscopic slides and were treated in 50% 
methanol and 50% acetone for 15 minutes. The sections were then air dried for 10 
minutes and stored at -20ºC (wrapped in foil) for further use or immediately stained. The 
air dried sections were placed in PBS (Optimax wash buffer) for 5 minute to rehydrate. 
The sections were then treated with the primary antibodies at specific dilution and 
incubated for 1 hour. The slides were subjected to 4 washes with PBS and then treated in 
universal multi- link biotinylated secondary antibody at a specific concentration. The 
slides were incubated for 30 minutes followed by 4 washes with PBS and then placed in 
avidin biotin complex (ABC- Vector Labs). Diaaminobenzidine tetrahydrochloride (3,3’-
diaminobenzidine) – DAB (Sigma) was added for 5 minutes to detect the bound antibody 
[DAB (3,3΄-diaminobenzidine) is a substrate for peroxidase and in the presence of H2O2 
brown coloured precipitate is formed indicating the presence of a specific protein when 
used in conjunction with specific antibodies].The slides were washed with water for 5 
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minutes and treated in Mayer’s haematoxyline for 1 minute followed by further wash with 
water for 10 minutes (nuclei become blue). The slides were then treated with methanol (3 
times) and clearing in 2 changes xyline before mounting under a cover slip. Negative 
controls (an irrelevant antibody instead of the primary antibody or PBS buffer) were used 
in this study. The concentrations of antibodies were different to each staining, details of 
which is explained separately in the relevant chapters. 
 
2.10 Knockdown of gene transcripts using Hammerhead Ribozyme Transgenes 
The hammerhead ribozyme transgenes was discovered by Forster et al in 1987 as a self 
cleaving domain in the RNA genome of different plant viroids (Forster and Symons et al., 
1987). It was then demonstrated that the Ribozyme transgenes can act as a catalyst for 
cleaving a variety of RNA targets by incorporating into short synthetic oligonucleotides 
(Haseloff and Gerlach et al., 1988). The ribozyme transgenes possess a typical secondary 
structure consisting of three helical stems with a catalytic core junction comprising of 
several invariant nucleotides (Figure 2.2).  
To knockdown a specific gene using a hammerhead ribozyme transgene, we designed 
primers according to secondary structure of the gene predicted by using Zuker’s RNA 
mFold software (Zuker et al., 2003). A suitable ribozyme target site was selected from 
within the secondary structure of the specific gene and the ribozyme designed to 
specifically bind and cleave the sequence surrounding this target site of the mRNA 
transcript using a touchdown PCR technique. The touchdown PCR conditions are shown 
below:  
• Step 1: Initial denaturating period – 94ºC for 5 minutes 
• Step 2: Denaturating step- 94ºC for 10 seconds 
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• Step 3: Annealing steps- 70ºC for 15 seconds, 65ºC for 15 seconds, 60ºC for 15     
seconds, 57ºC for 15 seconds, 54ºC for 15 seconds and 50ºC for 15 seconds 
• Step 4: Extension step- 72ºC for 20 seconds 
• Step 5: Final extension period of 72ºC for 7 minutes 
Step 2-4 were repeated over 48 cycles, comprising of 8 cycles for each different annealing 
temperature. Following this the ribozyme transgenes were inserted into the pEF6 plasmid 
in the TOPO cloning reaction as described later. After 4 weeks selection with a specific 
antibiotic, a stable cell line containing transgene was produced and verified using RT-
PCR and Western Blotting. This technique is used extensively and reported in our 
laboratory previously (Jiang et al., 2001, 2003b). Using this technique a hammerhead 
ribozyme transgene was constructed for the CREB 1 which is explained in detail in the 
respective chapter. 
 
 
 
 100 
 
 
 
 
 
 
 
 
Figure 2.2:  Two-dimensional structure of the hammerhead ribozyme 
 
N, any nucleotide; N′, nucleotide complementary to N; H, any nucleotide but G; Y, 
pyrimidine nucleotide; R, purine nucleotide complementary to Y 
(Adapted from Narendra K. Vaish et al., 1998) 
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2.11 Cloning and expression of PCR products 
Cloning is defined as the method by which PCR products are inserted into plasmid 
vectors for constitutive or induced expression in mammalian cell line. It involves the 
ligation of the PCR insert into the reading frame of the plasmid vector and requires the 
proper vector insert molar ratio (1:1-1:3) depending on vector. This technique enables a 
large number of copies of the PCR products to be synthesised.  
The design of primers is crucial for correct expression of PCR products in a vector. The 
PCR products should reveal a single discrete band to be used directly in the cloning 
reaction. Alternatively, if multiple bands are produced, the PCR reaction may require 
modification to optimise conditions, before subjecting to the cloning reaction. Through 
out this study cloning was performed using TOPO TA Cloning® kit (Invitrogen, Paisley, 
UK) in accordance with the manufacturer’s instructions. 
 
2.11.1 TOPO TA Cloning 
TOPO TA Cloning® TA Cloning System (TOPO Cloning) is extensively used and 
provides an extremely efficient one step cloning technique for the direct insertion of Taq 
polymerase- amplified PCR products into a plasmid vector. TOPO Cloning ligates the 
PCR product into the pEF6/V5-His-TOPO® plasmid vector with topoisomerase I. The 
vector has been engineered to be a linearized plasmid with 3' deoxythymidine (T) 
overhangs that is activated by being covalently bonded to topoisomerase I (Activated 
TOPO cloning vector).  The 3'A overhangs of the PCR product complement the 3'T 
overhangs of the vector and allow for fast ligation with the topoisomerase I. Once the 
PCR product is cloned into pEF6/V5-His-TOPO and transformants analyzed for the 
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correct orientation, the plasmid may be transfected into the mammalian cell line of 
choice. 
 
2.11.2 TOPO® Cloning Reaction  
The table below showed the ingredients required to set up TOPO® Cloning reaction to 
produce the recombinant vector for eventual transformation into chemically competent 
TOP10 One Shot® E. coli (Figure 2.3).  
Reagent     Volume (6 µl ) 
Fresh PCR product 2 µl 
Salt Solution 1 µl 
Water   2 µl  
TOPO® vector 1 µl 
 
The red colour of the TOPO® vector solution is used to visualize the solution. Inclusion 
of salt (final concentration of 200 mM NaCl, 10 mM MgCl2) allows for longer incubation 
times as it prevents topoisomerase I from rebinding and potentially nicking the DNA after 
ligating the PCR product and dissociating from the DNA. This results in more stable 
molecules leading to higher transformation efficiency.  
The solution was mixed gently and incubated for 5 minutes at room temperature (22°C -
23°C). Depending on the size of the PCR products the length of the TOPO® Cloning 
reaction can be varied from 30 seconds to 30 minutes. During incubation the PCR product 
ligates with the free end of the linear vector to form a circular plasmid. The reaction was 
then placed on ice and immediately proceeds to Transforming Competent Cells to avoid 
decrease in transformation efficiency. 
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                                   Determine strategy for PCR 
 
 
 
 
                                   Produce PCR product 
 
 
 
 
                                TOPO® cloning reaction 
 
 
 
 
                        Transform into TOP10 E. coli cells 
 
 
 
 
                              Select and analyze colonies 
 
 
 
 
     Prepare purified plasmid for transfection into mammalian cells  
 
 
 
 
Transfect mammalian cell lines and assay for expression of PCR product 
 
 
 
Figure 2.3: Flow Chart Showing the TOPO TA Cloning Method 
(Invitrogen web catalogue) 
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2.11.3 Transformation into Competent Cells (E. coli) 
After the TOPO® cloning reaction, we then transform the TOPO® construct into the One 
Shot® TOP10 Chemically Competent E. coli.  
Transforming One Shot® TOP10 Competent Cells (chemical transformation) 
Materials required for chemical transformation is outlined below 
• TOPO® Cloning reaction solution 
• S.O.C. medium  
• LB plates containing 50 µg/ml ampicillin  
• 40 mg/ml X-gal in dimethylformamide (DMF)  
• Water bath 
• 37°C shaking and non-shaking incubator  
For each transformation, we used one vial of competent cells and two LB plates.  
• Equilibrate a water bath to 42°C  
• Warm the vial of S.O.C. medium to room temperature.  
• Warm LB plates containing 50-100 µg/ml ampicillin at 37°C for 30 minutes  
• Spread 40 µl of 40 mg/ml X-gal on each LB plate and incubate at 37°C until ready 
for use.  
• Thaw on ice 1 vial of One Shot® cells for each transformation.  
2 µl of the TOPO® Cloning reaction solution was gently mixed into a vial of One Shot® 
Chemically Competent E. coli and incubated on ice for 30 minutes. The cells were then 
heat-shocked for 30 seconds in a 42°C water bath and the vial immediately transferred 
back on ice. Following this 250 µl of pre-warmed S.O.C. medium to room temperature 
was added to the vial and incubated at 37°C for 1 hour on an orbital shaker (200rpm). 
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After this 50 µl of transformed solution was then spread on a pre-warmed LB agar 
selective plate containing 50µg/ml ampicillin and incubated overnight at 37°C. 
 
2.12 LB (Luria-Bertani) medium and agar plates (1 litre) 
LB medium was prepared by dissolving 10g tryptone, 5g yeast extract, 10g NaCI in 950 
ml deionized water. We then adjusted the pH to 7.0 with NaOH, and the solution was 
made up to 1 litre. 15g of agar was then added to the solution and autoclaved. The 
solution was allowed to cool, during which time the desired antibiotic (Ampicillin 50µg/ 
ml) was added. The solution was poured into Petri dish plates (Bibby Sterlin Ltd., Staffd, 
UK) and allowed to set before being stored inverted at 4°C in a refrigerator. Ampicillin 
was added to the solution to select out the positive colonies containing the plasmid with 
the PCR sequence. The pEF6/V5-His-TOPO® plasmid contains an ampicillin resistance 
sequence which confers resistance to E. coli containing this plasmid to the ampicillin. 
Normally E. coli are sensitive to ampicillin and hence do not grow in the LB medium. 
50µl of the transformed solution was then evenly spread out in the LB agar plate and 
incubated overnight at 37ºC. 
 
2.13 Selection and Analysis of positive colonies 
Following overnight incubation, the LB agar plates were inspected for bacterial colonies 
containing the plasmid vector. We than analysed the colonies to identify the correct 
insertion and orientation of the target sequence in the plasmid to ensure that the resulting 
product is viable prior to amplification. 10-15 colonies were randomly selected and the 
plates marked and numbered over the selected positive colonies. After this we screened 
these bacterial colonies for the plasmid vector incorporating the PCR insert using RT-
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PCR. This is achieved through the use of the forward primer for the plasmid and the 
reverse primer for the insert. This ensures that the amplified products are that of the insert 
and the plasmid in the correct orientation prior to amplification.    
 
2.14 Amplification, extraction and purification of plasmid DNA  
Individual colonies producing the correct sized PCR product were identified and picked 
from the LB agar plate. This was then inoculated into 20ml of LB medium containing 
100µg/ml ampicillin in a polypropylene tube and incubated overnight at 37°C in a 
rotatory shaker (220rpm). Following this the resultant culture was added into 50ml of LB 
medium (with the appropriate antibiotic) and transferred into the conical flask. This was 
then incubated overnight at 37°C in a rotatory shaker. After this the solution was 
transferred to the universal container and centrifuged at 3000g for 15 minutes at 4ºC. The 
supernatant was discarded and the remaining pellet containing the E. coli were used for 
plasmid extraction. 
Plasmid was extracted and purified using the QIAGEN Mini Purification Kit (Qiagen, 
Crawley, UK) in accordance with the manufacturer’s protocol. 
The pellet was resuspended in 0.3ml of resuspension buffer which contains RNase 
inhibitors that inactivates any RNA contaminants. 0.3ml of cell lysis buffer was then 
added to the solution and mixed gently to avoid shearing of genomic DNA. The solution 
was incubated at room temperature for 5 minutes. 0.3ml of neutralization buffer was 
added to the solution and then incubated on ice for 5 minutes. The mixture was 
centrifuged at 13000rpm for 10minutes at 4ºC and the supernatant transferred to the pre-
equilibrated QIAGEN- tip (filter cartridge). This was then allowed to enter the resin by 
gravity flow and the plasmid DNA blinds to the ion-exchange resin within the filter 
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cartridge. The QIAGEN – tip was then washed 3 times with 1ml of medium salt buffer 
(QC wash buffer) to remove contaminants like RNA, proteins, dyes, and low molecular 
weight impurities from the plasmid preparation. The plasmid DNA was eluted from the 
QIAGEN –tip resin using 0.8ml of high salt buffer (QF buffer), and was collected in a 
2ml microfuge tube. The Plasmid DNA was then precipitated with 0.56ml of isopropanol 
and immediately centrifuged at 10000 rpm for 15 minutes. The pellet was then washed 2 
times with 1ml of 70% ethanol, centrifuged and air dried for 5 minutes. After this the 
pellet was resuspended in DEPC water. The yield of DNA was then determined through 
DNA quantisation using UV spectrophotometry at a wavelength of A260nm and Gel 
electrophoresis performed  using small amount of plasmid DNA to check both plasmid 
purity and size. The plasmid solution was stored at -20ºC. 
 
2.15 Electroporation (Transfection) of mammalian cells 
The purified plasmid DNA obtained as described above was incorporated into cultured 
mammalian cells utilising electroporation. The cells were harvested by trypsinisation of 
80-90% confluent cell culture as described above. The cell pellet obtained following 
centrifugation was mixed in 1 ml of complete medium and then placed on ice. 500µl of 
the cell suspension was transferred into electroporation cuvette and stored on ice. This 
technique was performed using the Easy jet Plus system (Flowgen, Staffordshire, UK). 
The parameters were set at 310 volts (to destabilise the cell wall integrity and hence 
allowing the plasmid DNA to cross the cell membrane to be integrated into the native 
cellular DNA) and a capacitance value of 1050µF. 10 µg of plasmid DNA was added to  
cell suspension in the electroporation cuvette, mixed gently and kept at room temperature 
for 2-5 minutes.  The cuvette was then loaded into the electroporator and a current of 310 
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volts was passed through the cuvette. The electroporated cells were immediately 
transferred into culture flask containing 5ml of pre-warmed culture medium and 
incubated at 37ºC with a humidified atmosphere of 5% CO2. 
Following this, isolation of a stable cell line expressing the gene of interest was achieved 
by harvesting cells in the culture medium containing 100µg/ml of G418. The 
electroporated cells were then allowed to grow till the cells are semi-confluent. The 
selective culture medium was changed every 2-3 days for 3-4 weeks to remove the dead 
cells and to allow colonies of resistant cells containing the plasmid and the inserted DNA 
to grow until sufficient numbers of cells were available for future experiments. Cells were 
routinely tested for the presence of the plasmid and insert, using RT-PCR.  
 
2.16 In vitro Functional Assays 
 
2.16.1 In vitro cell growth assay 
 
This is a simple assay for obtaining quantitative information of relative density of cells 
adhering to multi-well cluster dishes. The dye Crystal violet used in this assay stains 
DNA. Upon solubalization, the amount of dye taken up by the monolayer can be 
quantified in a spectrophotometer. The method is described below which has been 
previously reported by Jiang et al., 2005. 
Cells were detached from the culture flask and cell density per ml determined. Cells were 
then seeded into a 96 well plate equally (2500cells/well in 200l of normal medium) 
(Nunclon, Fisher Scientific, UK). Three sets of plates were incubated for 1, 3 and 5 days. 
Following this the medium was removed on the day of plating and the cells were fixed in 
10% formaldehyde for 30 minutes. This was followed by staining in 0.5% (w/v) crystal 
violet for 5 minutes. The plates were then washed and stain extracted with 10% acetic 
 109 
acid. The cell density was then determined by measuring the absorbance at a wavelength 
of 540nm by using a plate reading spectrophotometer (EL*800, Bio-Tek, Wolf 
Laboratories, UK). Cell Growth was determined as percentage increase and calculated by 
comparing the colorimetric absorbance obtained for each incubation period as follows: 
Percentage increase = (Day 3 or Day 5 absorbance) - Day 1absorbance/ Day 1 
absorbance. 
 
2.16.2 In vitro invasion assay 
 
The invasiveness of the breast cancer cells used in this study was determined using an In 
vitro Matrigel invasion assay model. This method was previously reported by Albini et 
al., 1987 and modified in our Laboratory (Jiang et al., 1995). This assay measures the 
cells ability to invade through an artificial basement membrane. The technique works 
upon the principle that a culture plate is equipped with an insert which has one end sealed 
with a polycarbonate membrane. The rationale behind using the polycarbonate membrane 
is that this membrane has a pore size of 8µm in diameter which allows cells to migrate 
through it. The surface of this membrane is coated with an extracellular matrix protein 
solution, matrigel (rich in basement membrane) (Becton-Dickinson Biosciences, Oxford, 
UK) to form a thin layer of gel matrix. Since this technique determines the capacity of 
tumour cells to penetrate through the gel matrix and porous membrane, it presents an 
indication of invasive capacity. The technique used during this study is described below. 
Twenty four well pre-chilled Cell culture inserts (Becton-Dickinson Biosciences, Oxford, 
UK) containing 8µm pores were coated in 50µg of Matrigel. To prevent irreversible 
gelling of Metrigel the following procedure was carried out at 4ºC. A stock solution and a 
working solution of Matrigel was prepared. 100µl (50µg) of working Matrigel solution 
was added to these cell culture inserts to form a thin even coating of Matrigel.  This was 
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then allowed to set and incubated at 45ºC in a drying oven. The inserts were then placed 
into twenty four well plates and the Matrigel layers were rehydrated by incubating at 
room temperature for 60 minutes using 300µl of sterile water. Following rehydration, the 
water was aspirated from each insert. Cell suspensions (15000 cells in 200µl of normal 
medium) were then added to each insert and incubated for upto 72 hours at 37ºC. 
Following this the Matrigel layer together with the non-invasive cells were removed from 
the inside of the insert using a cotton swab. The cells which had invaded into the Matrigel 
and migrated through the porous membrane to the underside of the insert were then fixed 
in 4% formaldehyde for 10 minutes at room temperature. Following this the cells were 
washed using distilled water and stained in 0.5 % crystal violet for 10 minutes at room 
temperature. Excess stain was removed by washing the cells with distilled water. The 
cells were then air dried and the numbers of invading cells (random fields) were counted 
using a light microscope. 
 
2.17 Statistical analysis 
Statistical analysis was performed using the Minitab 14 Statistical Software Package. The 
statistical comparisons were made using either a non-parametric Mann- Whitney test if 
the data was not normalised or a Students two tailed t- test if the data was found to be 
normalised and have equal variances. Graphs were constructed using Microsoft Excel 
Software Package.  
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CHAPTER 3 
 
EXPRESSION OF CREB 1 IN HUMAN BREAST CANCER AND THE ASSOCIATION 
WITH CLINICOPATHOLOGICAL CHARACTERISTICS 
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3.1 Introduction 
 
CREB belongs to a subfamily of the leucine zipper with basic domain (bZip) family of 
cellular transcription factors. CREB binds to the DNA sequence called the cyclic AMP 
response element (TGACGTCA) (Deutsch PJ et al., 1988)in the presence of cAMP to 
increase or  decrease gene transcription in response to extracellular signals. CREB 
mediates cellular responses to various mitogens and stressors. Various stress signals, 
growth factors and kinases promote phosphorylation –mediated activation of the CREB. 
cAMP responsive elements (CRE1 & CRE2) are essential for cAMP induced promoter II 
activity (Sofi et al., 2003). It requires phosphorylation by cAMP- dependent protein 
kinase at serine-119 and serine-133 (Johannessen et al., 2004) for interaction with DNA 
and RNA polymerase ІІ.  
It has been previously shown that CREB may act as a positive or negative transcription 
regulator in various human benign and malignant conditions (Luciani et al., 2003; Persani 
et al., 2000; Shankar et al., 2004; Perry et al., 2004; Dronadula et al., 2006; Melnikova et 
al., 2008; Deng et al., 2008 ; Catalano et al., 2009; Makhov et al., 2009; San-Marina et 
al., 2008) CREB is also involved in the regulation of various biological and cellular 
functions including cell survival, spermatogenesis, glucose homeostasis, circadian 
rhythm, memory and neuronal plasticity (Barton et al., 1996; Silva et al., 1998; De Cesare 
et al., 1999; Bonni et al., 1999 ; Travnickova-Bendova et al., 2002). It has been reported 
that CREB may act as a positive transcription regulator of aromatase and hence 
increased expression and oestrogen synthesis in breast cancer cells (Sofi et al., 2003). 
However, despite the extensive work on aromatase, little information is available on the 
expression and role of CREB in human breast cancer. There is no available data about the 
association of CREB with tumour or patients clinicopathological characteristics in human  
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breast cancer.  This study was carried out to investigate the expression pattern of CREB 
family of proteins in cohort of breast cancer and normal background tissue in relation to 
tumour histopathological grade, stage and nodal status. We also correlate the level of 
expression with the prognosis and clinical outcome of the patients. 
 
3.2 Materials and Methods 
RNA-extraction kit, RT (Reverse Transcriptase) kit and Mastermix for routine PCR and 
quantitative PCR were obtained from AbGene (Surrey, UK). PCR primers were designed 
using Beacon Designer (Palo Alto, CA, USA) and synthesized by Invitrogen (Paisley, 
Scotland, UK). Molecular-biology-grade agarose and DNA ladder were from Invitrogen. 
A first strand cDNA synthesis kit was purchased from Sigma Chemical Ltd. Low 
fluorescent 96 plates were obtained from Abgene and sealing films were from BIO- Rad 
(Hemel Hempstead, England, UK).  
 
3.2.1 Sample Collection 
Breast cancer tissues (n=120) and background tissue samples (normal breast tissue) 
(n=33) were collected (with ethical approval from local committee) immediately after 
surgery and stored in liquid nitrogen before processing. Patients were routinely followed 
after surgery and the median follow up period was 120 months for this study. The 
histopathological details, tumour grading (modified Bloom and Richardson’s grading 
system), tumour staging (TNM) and the prognostic index for the patients is shown in table 
3.1.  
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Table 3.1 - Clinical Information for breast tumour tissues analysed (n=120) 
 
 
Tissue Type 
Histological 
Grade (G) 
 
NPI and Node Status 
 
TNM 
 
Histology 
 
Outcome 
Backgound  
normal  breast  
tissue  n = 33 
     
 
Tumour  
 
 
n = 120 
 
G1 
G2 
G3 
 
 
n = 23 
n = 41 
n = 56 
 
NPI 1 
NPI 2 
NPI 3 
 
 
Node +ve 
Node -ve 
 
n = 66 
n = 38 
n = 16 
 
 
n = 55 
n = 65 
 
TNM 1 
TNM 2 
TNM 3 
TNM 4 
 
 
n =69 
n =40 
n =7 
n =4 
 
 
Ductal 
Lobular 
Other 
 
n =88 
n =14 
n =18 
 
Disease Free 
Metastasis 
Local recurrence 
Died of breast 
cancer 
Died of unrelated 
cause 
 
n =81 
n =7 
n =5 
 
n =20 
 
n =7 
 
 
• Histological Grade (Modified Richardson Bloom Classification) : G1 – Well Differentiated,             
G2 – Moderately Differentiated and G3 – Poorly Differentiated 
• NPI (Nottingham Prognostic Indicator): NPI = 0.2 x tumour size (cm) + lymph node stage                   
+ histological tumour grade (Galea MH et al., 1992). NPI 1 (Good prognosis) ≤ 3.4 NPI 2 
(Moderate prognosis)- Between 3.4 to 5.4 and NPI 3 (Poor prognosis)- ≥ 5.4  
• TNM: T- Tumour, N- Nodal and M- Metastasis  
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3.2.2 Tissue processing, RNA extraction and reverse transcription – polymerase 
chain reaction  
The frozen sections of breast tissue specimen were cut using a cryostat at a thickness of 
5–10 µm and stored at -20°C. Approximately 15–20 sections from each breast tissue 
sample were homogenized using a hand-held homogenizer in ice-cold RNA extraction 
buffer. The purity and the concentration of RNA were determined using agarose gel 
electrophoresis and UV spectrophotometer (Wolf Laboratories, York, UK). Reverse 
transcription was carried out from 1µg total RNA using a RT kit with an anchored oligo-
dT primer according to manufacturer’s instructions. The polymerase chain reaction (PCR) 
was performed with cDNA, master mix and the respective primers (Table 3.2)  using the 
following reaction conditions: 5 min at 95°C, 20 seconds at 94°C, 25 seconds at 56°C and 
50 seconds at 72°C for 36 cycles followed by final extension phase of 7 minutes at 72°C. 
ß-actin was used as a housekeeping gene and was amplified simultaneously using the 
primers as shown in the table. The PCR products were then separated on a 0.8% agarose 
gel, stained using ethidium bromide and visualized under UV lights.   
3.2.3 Quantitative analysis of CREB 1 Transcripts  
The transcript level of the CREB1  from the above-prepared cDNA was determined using 
a real-time quantitative PCR, based on the AmplifluorTM uniprimer technology (Intergen 
Company, Oxford, UK) modified from a previously reported method (Jiang et al.,  2004). 
Specific pair of PCR primers were designed using the Beacon Designer software (version 
2, Palo Alto, California, USA) and  to one of the primers (routinely the antisense primer 
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in our laboratory), an additional sequence, known as the Z sequence (5'-
actgaacctgaccgtaca-3'), which is complementary to the universal Z probe (IA Nazarenko 
et al., 1997) (Intergen, Oxford, UK) was added. Cytokeratin-19 (CK19) was used for 
comparison of cellularity during the analysis and primer for CK19 is shown in table 3.2. 
The reaction was carried out using the following: Hot-start Q-master mix (Abgene), 10 
pmol of specific forward primer, 10 pmol of reverse primer which has the Z sequence, 
100 pmol of 6-carboxyfluorescein (FAM)-tagged probe (Intergen), and cDNA from 
approximately 50ng RNA (calculated from the starting RNA in the reverse transcriptase 
reaction). The reaction was carried out using IcyclerIQTM (BioRad) which is equipped with 
an optic unit that allows real-time detection of 96 reactions, using the following 
conditions: 94°C for 5 minutes followed by 50 cycles at 94°C for 10 seconds, 55°C for 15 
seconds and 72°C for 20 seconds (Jiang et al., 2003a). The levels of the transcripts were 
generated from an internal standard that was simultaneously amplified with the samples, 
and are shown here in two ways: levels of transcripts based on equal amounts of RNA, 
and as a target/CK19 ratio.  
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Table 3.2: Primers sequences used in the quantitative RT- PCR 
 
Gene Primer Name Primer Sequence (5’-3’) 
 
Optimal 
Annealing 
Temperature 
Product Size ( 
bps) 
Accession no: 
CREB 1 F1 ggggactatgaggagatgat   
CREB 1 CREB 1 ZR actgaacctgaccgtacagtggaggtcttgatgtgaat  
 
55°C 
816  
NM_005171 
ß-actin F atgatatcgccgcgctcg 
ß-actinR cgctcggtgaggatcttca  
580 
NM_001101 
81-660 
ß-actin ZF ggacctgactgactacctca 
 
 
ß-actin 
ß-actin ZR actgaacctgaccgtacaagcttctccttaatgtcacg 
 
 
 
 55°C 117 
NM_001101 
622-720 
 
CK19 F caggtccgaggttactgac  
CK19 
CK19 ZR actgaacctgaccgtacacactttctgccagtgtgtcttc 
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3.2.4 Immunohistochemical staining of the CREB-1 proteins  
Immunohistochemical staining was carried out using frozen sections of breast tumour and 
normal mammary tissue cut at a thickness of 6µm using a cryostat. The sections were 
mounted on Super Frost Plus microscopic slides and air-dried for 20-30 minutes. The 
fixed tissue sections were treated in 50% methanol and 50% acetone for 15 minutes. The 
sections were then air dried for 10 minutes and stored at -20ºC (wrapped in foil) for 
further use or immediately stained. The air dried sections were placed in PBS (Optimax 
wash buffer) for 5 minute to rehydrate. The sections were treated with the primary 
antibodies (Santa Cruz Biotechnology, Santa Cruz, California, USA)  at specific dilution 
and incubated for 1 hour. The slides were subjected to 4 washes with PBS and then 
treated in universal multi- link biotinylated secondary antibody (Sigma, Poole, Dorset, 
UK) at a specific concentration. The slides were incubated for 30 minutes followed by 4 
washes with PBS and then placed in avidin biotin complex (ABC- Vector Labs). 
Diaminobenzidine tetrahydrochloride (3,3-diaminobenzidine) – DAB (Sigma) was added 
for 5 minutes to detect the bound antibody. [DAB (3,3΄-diaminobenzidine) is a substrate 
for peroxidase and in the presence of H2O2 a brown coloured precipitate is formed 
indicating the presence of a specific protein when used in conjunction with specific 
antibodies].The slides were washed with water for 5 minutes and treated in Mayer’s 
haematoxyline for 1 minute followed by further wash with water for 10 minutes (nuclei 
become blue). The slides were then treated with methanol (3 times) and clearing in 2 
changes xyline before mounting under a cover slip. Negative controls (an irrelevant 
antibody instead of the primary antibody or PBS buffer) were used in this study. The 
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concentrations of antibodies were different to each staining. Staining of the respective 
proteins was quantified using Optimas 6.0 software as described below.  
3.2.5 Quantification of CREB expression in breast cancer tissues 
Quantification of expression of these proteins and immunohistochemical grading were 
carried out as described by Paleri et al. (Paleri et al., 2001). The staining was assessed on 
random pattern fields and grading performed on a four point scale. The grading was 
scored as 0 = negative, 1 = weakly positive, 2 = positive and 3 = strongly positive.  This 
scoring was carried out by two independent observers and any disparity in the findings 
was resolved by re-evaluation of the slides.  
Statistical analysis was carried out as described in section 2.17 
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3.3 Results 
We screened three breast cancer lines (MDA-MB-231, MCF 7 and MDA- MB- 453) to 
assess the expression of CREB 1, using RT-PCR. The mRNA level of CREB 1 in these 
cell lines are illustrated in Figure 3.1. CREB 1 was expressed at a relatively higher level 
in MDA-MB- 231 and MCF 7 cell lines and was detectable in MDA- MB- 453 cell line. 
Human fibroblast cell line MRC5 and endothelial cell line HECV had very low levels of 
CREB1. 
 
 
Figure 3.1: The expression of CREB 1 in breast cell lines, fibroblast and 
endothelial cell lines was assessed using RT- PCR. 
40 cycles were performed for these PCR reactions. ß-actin was used a housekeeping 
control. 
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3.3.1 Expression of CREB 1 in normal mammary and breast cancer tissues  
We analysed the expression pattern of CREB-1 in both normal mammary and tumour 
tissues using the real time quantitative RT-PCR. As shown in Figure 3.2 breast tumour 
tissues had higher level of CREB-1 as compared to normal breast tissues (p=0.0092) 
(Table 3.3).  
Table 3.3: Means and standard deviation of the levels of expression of CREB 1 in 
normal and breast cancer tissues. 
 
 
 
 CREB1  CREB 1: CK19 
ratio 
 
Normal 3.7 ± 1.35  720 ± 232  
Cancer 12.5 ± 1.82 p=0.0092 
 
519 ± 105 p=0.43 
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Figure3.2a: Quantitative real time PCR demonstrating high expression of 
CREB 1, in tumour samples as compared to normal mammary tissue. 
Figure3.2b: Transcript normalised by CK19 (shown as CREB-1: CK19 
ratio).  
 
 123 
3.3.2 Expression of CREB 1 and its correlation with nodal involvement 
As shown in Figure 3.3a, there was a significantly higher level of the CREB-1 transcript 
in node positive tumours as compared to node negative tumours (Table 3.4 ) The same 
trend was seen when CREB-1 transcript was normalized by CK19 (Figure 3.3b & Table 
3.4).  
Table 3.4: Means and standard deviation of the levels of expression of CREB 1 in 
relation to nodal status. 
 
 CREB1  CREB1:CK19 
ratio 
 
Node -ve 6.2 ± 1.8  238 ± 85  
Node +ve 26.5 ± 3 p=0.0018 680 ± 149 p=0.0004 
3.3.3 Expression of CREB family proteins and its relation to tumour grade 
As shown in Figure 3.4a, Grade-2 carcinoma (19.3 ± 3.6, p=0.075) and grade-3 (7.9 ± 
2.5, p=0.1131) had higher level of CREB-1 expression as compared to grade-1 (3.4 ± 3.7) 
carcinoma but were not statistically significant. The same trend was seen with Grade 3 
tumours when CREB-1 transcript was normalized by CK19 but interestingly Grade 1 
carcinoma had higher level of CREB-1 expression as compared to grade-2 (Figure 3.4b & 
Table 3.5).  
Table 3.5: Means and standard deviation of the levels of expression of CREB 1 in 
relation to tumour grade. 
 
 CREB1  CREB1:CK19 
ratio 
 
Grade 1 3.4 ± 3.7  448 ± 214  
Grade 2 19.3 ± 3.6 p=0.075 357 ± 112 p=0.73 
Grade 3 7.9 ± 2.5 p=.1131 535 ± 135 p=0.76 
 124 
CREB 1
0
5
10
15
20
25
30
35
NODE - NODE+
Tr
an
sc
rip
t L
ev
el
s/
 
50
n
g 
m
R
N
A
 
CREB1:CK19 ratio
0
100
200
300
400
500
600
700
800
900
NODE - NODE+
Tr
an
sc
rip
t L
ev
el
s/
 
50
n
g 
m
R
N
A
 
 
 
Figure3.3a: RT –PCR analysis of breast cancer tissue samples, showing higher 
transcript levels of CREB 1 in node positive tumours as compare to node 
negative tumours. 
Figure3.3b: Transcript normalised by CK19 (shown as CREB-1: CK19 ratio). 
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Figure3.4a: Levels of CREB1 in relationship with tumour grade. 
Figure3.4b: Transcript normalised by CK19 (shown as CREB-1: CK19 ratio). 
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3.3.4 Tumours from patients with aggressive disease had higher levels of the CREB-
1 transcript 
Nottingham prognostic index was used as a tool to determine the prognosis of the 
patients. NPI< 3.4 was regarded as having a good prognosis (NPI-1), 3.3-5.4 moderate 
(NPI-2) and >5.4 as poor prognosis (NPI-3). As shown in Figure 3.5a, there was 
significantly higher level of CREB-1 transcript in patients with moderate (30.8 ± 4.1, 
p=0.0036) and poor prognosis (13.2 ± 2.2, p=0.0061) as compared to patients with good 
prognosis (6.2 ± 1.8) (Table 3.6). The same trend was seen when CREB-1 transcript was 
normalized by CK19 (Figure 3.5b). Based on TNM staging the expression of CREB 1 is 
markedly raised in TNM 3 tumours but was statistically not significant (Table 3.7). 
Interestingly the expression of CREB 1in stage 4 tumour was decreased as compared to 
stage 1 tumour (Figure 3.6a)  but when normalised by CK19 the expression of CREB 1 
increases dramatically as compared to stage 1 & 2 tumours (Figure 3.6b). 
Table 3.6: Means and standard deviation of the levels of expression of CREB 1 in 
relation to patient prognosis using the Nottingham Prognostic Index (NPI) 
 
 CREB1  CREB 1: CK19 ratio  
NPI 1 6.2 ± 1.8  238 ± 85  
NPI 2 30.8 ± 4.1 p=0.0036 730 ± 190 p=0.0050 
NPI 3 13.2 ± 2.2 p=0.0061 553 ± 215 p=0.0018 
 
Table 3.7: Means and standard deviation of the levels of expression of CREB 1 in 
relation to tumour stage using the TNM classification. 
  
 CREB1  CREB1:CK19 ratio  
TNM 1 15 ± 1.7  389 ± 108  
TNM 2 6.4 ± 4.1 p=0.79 490 ± 146 p=0.58 
TNM 3 23.5 ± 4 p=0.0928 594 ± 441  p=0.76 
TNM 4 7.9 ± 5.1 p=0.699 2040 ± 1659 p=0.39 
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Figure3.5a: CREB-1 and predicted clinical outcome, using the Nottingham 
Prognostic Index (NPI) as an indicator 
Figure3.5b: Transcript normalised by CK19 (shown as CREB-1: CK19 ratio). 
(NPI-1 - good prognosis group, NPI-2 - moderate prognosis group and NPI-3 - poor 
prognosis group) 
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Figure3.6a: Levels of CREB1 in relationship with TNM Staging. 
Figure3.6b: Transcript normalised by CK19 (shown as CREB-1: CK19 ratio).   
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3.3.5 High levels of the CREB family protein transcript was linked to both the 
overall and disease-free survival of the patients 
Following a median 120 months follow up, patients were divided into the following 
groups: those who remained disease free, who developed metastasis  or local recurrence 
and those who died of breast cancer related disease (excluding non – cancer related 
deaths). As shown in figure 3.7a, CREB 1 level was high in patients who developed 
metastasis (41 ± 4.6) and who died of breast cancer (24.2 ± 5.2) related cause as 
compared to patients who remained disease free (8.9 ± 2.3) but were statistically not 
significant. Interestingly, when normalised by CK19 a significant difference was seen in 
tumours from patients who died of breast cancer (p=0.0003; Figure 3.7b & Table 3.8). 
We combined the three groups (with metastasis, recurrence and mortality), to form a poor 
prognostic group (referred to as poor prognosis in figure 3.8a) and compared this group 
with those who remained disease free. It was demonstrated that CREB 1 level was higher 
in patients with poor prognosis (26.5 ± 3) but was statistically not significant. When 
normalised with CK19 a highly significant difference was seen in patients with poor 
prognosis (p=0.0035). (Figure 3.8b & Table 3.9) We have divided patients into groups 
with high levels of CREB 1, by using the NPI as a general guide. When the level of 
CREB 1 transcript is higher than the mean of NPI-2 (3.4-5.4, moderate prognostic group), 
the tumour is arbitrarily regarded as having a high level. When long term survival was 
analysed using Kaplan-Meier survival method, patients with high levels of CREB1 had a 
significantly shorter disease free survival {95.3 (68.4-122.3) months} compared with 
those with lower levels {133.9 (123.5-144.2) months}, p=0.0193 (figure 3. 9).  
 130 
 
 
Table 3.8: Means and standard deviation of the levels of expression of CREB 1 in 
relation to clinical outcome 
(median follow- up 120 months). 
 
 CREB1  CREB1:CK19 
ratio 
 
Disease Free 
Survival 
8.9 ± 2.3  375 ± 120  
Metastasis 41 ± 4.6 p=0.089 692 ± 640 p=0.65 
Local 
Recurrence 
5 ± 1.6 p=0.288 516 ± 502 p=0.89 
Death (Breast 
Cancer) 
24.2 ± 5.2 p=0.326 1215 ± 295 p=0.0003 
 
 
 
 
 
Table 3.9: Means and standard deviation of the levels of expression of CREB 1 in 
patients who remained disease free and who had disease progression 
 
 CREB1  CREB1:CK19 
ratio 
 
Disease Free 
Survival 
8.9 ± 2.3  375 ± 120  
Poor Prognosis 26.5 ± 3 p=0.2998 
 
999 ± 239 p=0.0035 
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Figure3.7a: CREB-1 transcript levels and clinical outcome (median follow- up 
120 months) 
Figure3.7b:  Transcript normalised by CK19 (shown as CREB-1: CK19 ratio). 
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Figure3.8a: Comparison between patients who remained disease free and who 
had disease progression (recurrence, metastasis and mortality). 
Figure3.8b: Transcript normalised by CK19 (shown as CREB-1: CK19 ratio). 
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Figure3.9: Kaplan- Meier survival analysis showing correlation between 
CREB-1 transcript levels and the disease free survival. 
Patients with high levels of CREB1 had a significantly shorter disease free survival 
(95.3 (68.4-122.3, 95%CI) months) compared with those with lower levels (133.9 
(123.5-144.2) months), p=0.0193. Patients divided into groups with high and low 
levels of CREB 1 by using NPI as a general guide as explained earlier. 
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3.3.6 Distribution of CREB 1 protein in breast cancer and normal mammary tissue 
We examined the presence of CREB-1 in mammary tissue using immunohistochemical 
staining.  CREB-1 staining was primarily seen in nucleus of both normal and tumour 
cells. The staining pattern of CREB-1 in tumour tissue and in normal (background) 
mammary tissue was then compared. As shown in Figure 3.10 CREB-1 is mainly 
localised in the nucleus both in normal mammary tissue and the tumour tissue. Semi –
quantitative analysis of the 8 paired (normal and tumour tissue) samples showed that 
CREB 1 staining in normal mammary tissue was weaker as compared with the tumour 
tissue (Figure 3.10 & Table 3.11). Using a Chi-square test, there was a significant 
difference between background normal and cancer tissues (Chi square value=16, 
p=0.001). By grouping negative and weakly positive, positive and strongly positive 
(Table-3.11) and using Fisher's Exact test, there was a significant difference between 
background normal and cancer tissues (p<0.0001). 
3.3.7 Immunostaining of CREB 1 in relation to tumour prognosis (Nottingham 
prognostic Index – NPI), TNM stage and tumour grade 
The level of CREB 1 expression is higher in the grade 3 tumours as compared to grade 1 
tumours. Of the 6 G3 samples (background =3 and tumour =3), 5 samples staining was 
scored as 3+ for CREB 1 whereas out of the 6 G1 samples (background =3 and tumour 
=3), G1 tumours were scored negative (0) or weakly positive (+1) (Table 3.12, Figure 
3.11).  Similar trend was seen in NPI 3 and TNM 4 tumours as compared to NPI 1 and 
TNM 1 tumours respectively (Table 3.12, Figure 3.12 & 3.13).  
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Table 3.10 Pathological characteristics of Breast Cancer 
 
GRADE TNM NPI 
GRADE 1  n =  3 
GRADE 2  n =  2 
GRADE 3  n =  3 
TNM 1  n  =  2 
TNM 2  n  =  1 
TNM 3  n  =  2 
TNM 4  n  =  3 
NPI 1  n  =  2 
NPI 2  n  =  3 
NPI 3  n  =  3 
 
Table 3.11 Immunohistochemistry staining scores of CREB 1 in normal and cancer 
tissue specimen 
 
negative or weakly 
positive 
positive or strongly 
positive 
CREB1 
 
0 +1 +2 +3 
Normal 2   6   0   0 
Cancer 0   0   3   5 
 
Table 3.12 Immunohistochemistry staining scores of CREB 1 in relation to tumour 
grade, TNM stage and Nottingham Prognostic Index (NPI) 
 
CREB1 Background Cancer 
IHC 0   +1   +2   +3 0   +1   +2   +3 
 
GRADE 1  n  =  3 
GRADE 2  n  =  2 
GRADE 3  n  =  3 
 
 
3     0      0     0 
0     1      1     0 
0     0      1     2 
 
1     2    0      0 
0     1    1      0 
0     0    0      3 
 
TNM 1  n  =  2 
TNM 2  n  =  1 
TNM 3  n  =  2 
TNM 4  n  =  3 
 
 
2     0    0      0 
1     0    0      0 
0     0    1      1 
0     0    0      3 
 
1     1    0      0 
0     1    0      0 
0     0    0      2 
0     0    1      2 
 
NPI 1  n  =  2 
NPI 2  n  =  3 
NPI 3  n  =  3 
 
 
1     1    0      0 
0     0    1      2 
0    0     2      1 
 
0     2    0      0 
0     0    1      2    
0     0    0      3 
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Figure3.10: Immunohistochemical staining of CREB-1 in normal mammary 
and tumour tissue  
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Figure3.11: CREB 1 immunostaining in breast cancer tissue. 
Grade 3 tumour displayed strong immunoreactivity for CREB 1 as compared to Grade 1 
tumour which showed weak immunostaining. 
  
Figure 3.12: CREB 1 immunostaining in breast cancer tissue. 
TNM 4 tumour displayed strong immunoreactivity for CREB 1 as compared to TNM 1 
tumour which showed weak immunostaining. 
  
Figure 3.13: CREB 1 immunostaining in breast cancer tissue. 
NPI 3 tumour displayed strong immunoreactivity for CREB 1 as compared to NPI 1 
tumour which showed weak immunostaining 
 138 
 
3.4 Discussion 
Aberrant transcriptional activity and expression of CREB in cancer cells and clinical 
tumours has long been recognised. This molecule has been extensively studied in relation 
to stress response (Sabban et al., 2006), memory (Wagatsuma et al., 2006) and in solid 
tumours, both benign and malignant (Luciani et al., 2003; Perry et al., 2004). This protein 
behaves as both negative and positive regulatory proteins in different solid tumours. Chen 
et.al reported that in cancer tissue increased levels of positive regulatory proteins like 
ERRalpha -1 and CREB-1 is present as compared to negative regulatory proteins like 
EAR-2, COUP-TFI, Snail and Slug proteins (Chen et al., 2005). Coxon et al. have shown 
a link between an oncogenic chromosomal translocation and CREB activation in 
malignant salivary gland tumours (Coxon et al., 2005). Sofi et al reported that the 
expression of CREB in tumour bearing breast adipose tissue is higher than the normal 
breast adipose tissue (Sofi et al., 2003). CREB has an antimitogenic role in solid tumours 
like glioblastoma proliferation (Perry et al., 2004) and decreased expression is seen in  
thyroid carcinoma (Luciani et al., 2003).  
This study has found that CREB 1 is expressed in both tumour tissues and the normal 
breast adipose tissues with higher levels in tumour tissues. CREB 1 was shown to be 
predominantly a nucleus protein which was highly stained in breast cancer cells nucleus 
as compared with normal epithelial cells.  
The current study reported for the first time that CREB 1 is aberrantly expressed in 
human breast cancer at mRNA levels and has significant bearing to the clinical outcome 
of the patients. We assessed CREB-1 level in breast cancer tissue samples against the 
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known prognostic factors and found significantly raised levels of CREB1 in patients with 
poor prognosis, metastatic disease and nodal involvement. The study has revealed a 
significant link between CREB 1 and mortality, in that high levels are associated with 
shorter disease free survival.  
The immunohistochemical based analysis has shown similar findings to that of 
quantitative transcript analyses. However, due to the limited availability of the tissue 
materials for histological analysis, IHC assay was only conducted on a small number of 
samples, which preclude the possibility to carry out an appropriate statistical analysis, 
namely in Grade and NPI subgroups. Based on the favourable IHC results, it will be 
highly useful to conduct a full range IHC analysis on a suitable cohort of breast tumour 
tissues in future.  
The role of CREB in relation to aromatase expression is still unclear. Over-expression of 
aromatase in adipose tissue surrounding breast tumour could arise through increase in 
both CREB expression and CREB transcriptional activity. Sofi et al. reported that there is 
increase aromatase expression due to increase in CREB induced promoter II activity in 
tumour bearing breast adipose tissue(Sofi et al., 2003). Further studies needs to be done 
whether increased expression of CREB leads to aberrant aromatase expression and 
whether there is simultaneous decrease in the expression of the negative regulatory 
proteins like Snail and Slug proteins in breast cancer tissue. 
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CHAPTER 4 
 
EXPRESSION OF ATF 1, ATF 2 AND ATF 3 IN HUMAN BREAST CANCER AND 
THE ASSOCIATION WITH CLINICOPATHOLOGICAL CHARACTERISTICS 
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4.1 Introduction  
Transcription factors play a vital role in the process of tumourigenesis as they possess 
specific structural features that encode transactivating or repressing functions. Breast 
cancer results from acquired or inherited gene defects resulting in the expression of 
abnormal transcriptional factors which in turn leads to increased proliferation of 
transformed mammary cells (Jackson et al., 1998; Loeb et al., 1998).  
Activating transcription factor (ATF) protein belongs to a subfamily of the bzip family of 
transcription factors that may act as transcriptional activators or repressors (Hai et al., 
1989). All members of this family share significant sequence similarity within a leucine 
zipper DNA- binding motif and an adjacent basic region. 
ATF protein is involved in both the positive and negative regulation of smooth muscle 
cell growth and motility. ATF-1 mediates protease activated receptor- 1 induced DNA 
synthesis in vascular smooth muscle cells (Ghosh et al., 2002).   
ATF 3 has been implicated in various processes including stress response, HBV-mediated 
processes and tumourigenecity. ATF3 interacts with the hepatitis B virus X protein which 
is implicated in HBV mediated hepatocarcinogenesis and apoptosis. ATF3 has been 
shown to play an important role in metastatic processes in melanoma and has a 
tumourigenecity- inhibiting effect on the HT29 colon cancer cells (Ishiguro et al.,  2000). 
Allen and Jennings demonstrated that ATF3 is induced during pancreatic stress such as 
partial pancreatectomy and ischemia –reperfusion of the pancreas (Allen and Jennings et 
al., 2001). 
ATF3 has also been demonstrated to activate transcription when coexpressed with other 
proteins such as HTLV-1 Tax (Barnabas et al., 1997; Low et al., 1994), Ras (Nilsson et 
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al., 1997), and PKA (Chu et al., 1994). ATF3 increases following exposure of cells to the 
signals and targets genes like gadd153/chop10 (Wolfgang et al.,  1997; Fawcett et al.,  
1999), E- selectin (Nawa et al.,  2000 ) and phosphoenolpyruvate carboxykinase (Allen-
Jennings et al.,  2002 ) 
Till date there is no available data about the association of ATFs with tumour or patients 
clinicopathological characteristics in human breast cancer.  This study was carried out to 
investigate the expression pattern of ATFs family of proteins in cohort of breast cancer 
and normal background tissue in relation to tumour histopathological grade, stage and 
nodal status. We also correlate the level of expression with the prognosis and clinical 
outcome of the patients. 
 
4.2 Material and Methods 
RNA-extraction kit, RT (Reverse Transcriptase) kit and Mastermix for routine PCR and 
quantitative PCR were obtained from AbGene (Surrey, UK). PCR primers (Table: 4.1) 
were designed using Beacon Designer (Palo Alto, CA, USA) and synthesized by 
Invitrogen (Paisley, Scotland, UK). Molecular-biology-grade agarose and DNA ladder 
were from Invitrogen (see section 3.2) 
 
4.2.1 Sample Collection 
Breast cancer tissues (n=120) and background tissue samples (normal breast tissue) 
(n=33) were collected (with ethical approval from local committee) immediately after 
surgery and stored in liquid nitrogen before processing. Patients were routinely followed 
after surgery and the median follow up period was 120 months for this study. The 
histopathological details, tumour grading (modified Bloom and Richardson’s grading 
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system), tumour staging (TNM) and the prognostic index for the patients is shown in 
chapter 3  (For detail see section 3.2.1  and  Table 3.1 ) 
4.2.2 Tissue processing, RNA extraction and reverse transcription – polymerase 
chain reaction  
For detail see section 3.2.2 
4.2.3 Quantitative analysis of ATF Transcripts  
The transcript level of the ATF from the above-prepared cDNA was determined using a 
real-time quantitative PCR, based on the AmplifluorTM uniprimer technology (Intergen 
Company, Oxford, UK). (For detail see section 3.2.3) The reaction was carried out as 
explained previously, using the following conditions: 94°C for 5 minutes followed by 50 
cycles at 94°C for 10 seconds, 55°C for 15 seconds and 72°C for 20 seconds. The levels 
of the transcripts were generated from an internal standard that was simultaneously 
amplified with the samples, and are shown as levels of transcripts based on equal amounts 
of RNA.   
4.2.4 Immunohistochemical staining of the ATF proteins  
Immunohistochemical staining was carried out using frozen sections of breast tumour and 
normal mammary tissue as explained in section 3.2.4. However, given that ATF proteins 
are nucleus in their cellular location, modifications were carried out in order to visualise 
the nucleus distribution of the protein. At the end of DAB colour development, the slides 
were dried and mounted. The first evaluations were carried out by examining the brown 
staining in nucleus of the cells. Subsequently, all the slides were placed in Xylene for 
overnight in order to remove the coverslips. After removal of the cover slips, the slides 
were series treated using fresh xylene (X2), pure ethanol (X2), 90% Ethanol (X2), 70% 
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Ethanol (X2) and 50% Ethanol (X2), before finally merged in water and stained with 
hematoxyline to counter stain the nucleus. Images are presented here as both counter 
stained and non-conterstained. 
Statistical analysis was carried out as described in section 2.17 
 
 
Table 4.1: Primers sequences used in the quantitative RT- PCR 
 
 
Gene Primer 
Name 
Primer Sequence (5’-3’) 
 
Optimal 
Annealing 
Temperature 
Product Size 
( bps) 
Accession 
no: 
ATF1F1 ttctcatattgctcaacaggt 
  
 
ATF1 
ATF1 
ZR 
actgaacctgaccgtacactttctgtgaggagcctatg 
 
 
55°C 
 
816  
NM_005171 
ATF2F1 cttgccatgagaaaaagaat 
 
 
ATF2 
ATF2ZR actgaacctgaccgtacagaaagggtttgtcatcactc 
 
 
55°C 
 
2117 
NM_001880 
ATF3F1 gcgacgagaaagaaataaga 
 
 
ATF3 
ATF3ZR actgaacctgaccgtacatcaatctgagccttcagttc 
 
55°C 
 
1914 
NM_001674 
ß-actin F atgatatcgccgcgctcg 
ß-actinR cgctcggtgaggatcttca  
580 
NM_001101 
81-660 
ß-actin 
ZF 
ggacctgactgactacctca 
 
ß-
actin 
ß-actin 
ZR 
actgaacctgaccgtacaagcttctccttaatgtcacg 
 
 
 
55°C 117 
NM_001101 
622-720 
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4.3 Results 
We screened three breast cancer lines (MDA-MB 231, MCF 7 and MDA- MB 453) to 
assess the expression of ATF 1, ATF 2 and ATF 3, using RT-PCR. The mRNA level of 
ATF 1, ATF 2 and ATF 3 in these cell lines are illustrated in Figure 4.1. ATF 1 was 
expressed at a relatively higher level in all the three breast cancer cell line. ATF 2 and 
ATF 3 were expressed at a higher level in MDA- MB 453 cell line as compared to MDA-
MB 231 and MCF 7 cell lines (Figure 4.1) 
 
Figure 4.1: The expressions of ATF 1, ATF 2 and ATF 3 in human breast cancer, 
fibroblast and endothelial cell lines were assessed using RT- PCR. 
40 cycles were performed for these PCR reactions. 
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4.3.1 Expression of ATFs in normal mammary and breast cancer tissues  
We first analysed the overall expression levels of ATF 1, ATF 2 and ATF 3 in normal 
mammary and tumour tissues using the real time quantitative RT-PCR. As shown in 
figure the expression of ATF 1 transcript  is  significantly higher in breast tumour tissues 
as compared to normal mammary tissue (Figure 4.2 & Table 4.2). The expression of ATF 
2 and ATF 3 is higher in tumour tissue but no statistical significant difference was seen  
as compared to normal breast tissue (Figure 4.2 & Table 4.2). 
4.3.2 Expression of ATFs and its correlation with nodal involvement and tumour 
grade 
We then analysed the expression pattern of ATF 1, ATF 2 and ATF 3 in various tumour 
characteristics and interestingly we demonstrated that the level of expression of ATF 1, 
ATF 2 and ATF 3 transcript is higher in node negative tumours as compared to node 
positive tumours (Figure 4.3 & Table 4.3). The expression of ATF 1, ATF 2 and ATF 3 is 
higher in grade 1 tumour as compared to grade 3 tumour (Figure 4.4 and Table 4.4) but no 
statistical significant difference was seen.  
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Figure 4.2: Quantitative real time PCR demonstrating high expression of ATF 1, 
ATF 2 and ATF 3 in tumour samples as compared to normal mammary tissue. 
 
 
 
Table 4.2: Means and standard deviation of the levels of expression of ATF 1, 
ATF 2 and ATF 3 in normal and breast cancer tissues. 
  
 ATF1  ATF 2  ATF 3  
Normal 5 ± 2.3  1.5 ± 0.96  28.7 ± 11.5  
Cancer 46.7 ± 20.7 p=0.048 44.3 ± 27.6 p=0.12 32.6 ± 10.1 p=0.8 
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Figure 4.3: RT –PCR analysis of breast cancer tissue samples, showing low 
transcript levels of ATFs in node positive tumours as compare to node negative 
tumours.  
 
Table 4.3: Means and standard deviation of the levels of expression of ATF 1, ATF 2 
and ATF 3 in relation to nodal status. 
 
 ATF1  ATF 2  ATF 3  
Node -ve 73 ± 39  49 ± 45  44 ± 19  
Node +ve 19.1 ± 9.8 p=0.18 4.6 ± 2.3 p=0.33 17 ± 3.6 p=0.16 
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Figure 4.4: Levels of ATF 1, ATF 2 and ATF 3 in relationship with tumour 
grade. 
 
 
Table 4.4: Means and standard deviation of the levels of expression of ATF 1, ATF 2 
and ATF 3 in relation to tumour grade. 
 
 ATF1  ATF 2  ATF 3  
Grade 1 205 ± 120  133 ± 128  67.9 ± 48.8  
Grade 2 28.3 ± 14.4 p=0.16 10.6 ± 7.2 p=0.35 17.7 ± 4.5 p=0.32 
Grade 3 7.1 ± 1.6 p=0.12 4.3 ± 2.4 p=0.33 23.1 ± 8.6 p=0.38 
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4.3.3 Expression of ATFs and its relation to tumour prognosis 
Nottingham prognostic index was used as a tool to determine the prognosis of the 
patients. NPI< 3.4 was regarded as having a good prognosis (NPI-1), 3.4-5.4 moderate 
(NPI-2) and >5.4 as poor prognosis (NPI-3). As shown in figure, there was significantly 
higher level of ATFs transcript in patients with good prognosis as compared to patients 
with moderate and poor prognosis tumour (Figure 4.5 and Table 4.5).  The expression of 
ATF1 and ATF3 is markedly raised in TNM 1 and TNM 2 tumours as compared to TNM 
4 tumours. Interestingly the expression of ATF 2 in stage 4 tumour is high as compared to 
stage 1 tumour (Figure 4.6, Table 4.6) 
4.3.4 High levels of the ATFs family protein transcript was linked to both the overall 
and disease-free survival of the patients 
Following a median 120 months follow up, patients were divided into the following 
groups: those who remained disease free, who developed metastasis  or local recurrence 
and those who died of breast cancer related disease (excluding non – cancer related 
deaths). As shown in figure, Patients with metastatic disease and with local recurrence 
had low levels of the three ATFs, when compared with patients who remained disease 
free. Most interestingly, patients who died of breast cancer had a markedly reduced levels 
of ATF-1 and ATF-3 as compared with the patient who remained disease free (Figure 4.7 
and Table 4.7).  
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We combined the three groups (with metastasis, recurrence and mortality), to form a poor 
prognostic group (referred to as poor prognosis in figure 4.8) and compared this group 
with those who remained disease free. It was demonstrated that patients with predicted 
good prognosis had higher levels of ATF transcripts (73.1±38.7 ATF1, 49.4±45.4 ATF2 
and 44.0±18.6 ATF-3), than those with poor prognosis (6.1±2.6, 8.9±7.7 and 19.3±8.5 for 
ATF-1, -2 and -3 respectively) (Figure 4.8 and Table 4.8). 
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Figure 4.5: ATFs and predicted clinical outcome, using the Nottingham 
Prognostic Index (NPI) as an indicator 
(NPI <3.4 - good prognosis group, NPI 3.4-5.4 - moderate prognosis group and NPI > 
5.4 - poor prognosis group) 
Table 4.5: Means and standard deviation of the levels of expression of ATF 1, ATF 2 
and ATF 3 in relation to patient prognosis using the Nottingham Prognostic Index 
(NPI) 
  
 ATF1  ATF 2  ATF 3  
NPI 1 73.1 ± 38.7  49.4 ± 45.4  44 ± 18.6  
NPI 2 24.3 ± 13.7 p=0.24 2.8 ± 0.9 p=0.31 16.1 ± 3.9 p=0.15 
NPI 3 6.1 ± 2.6 p=0.089 8.9 ± 7.7 p=0.38 19.3 ± 8.5 p=0.23 
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Figure 4.6: Levels of ATF 1, ATF 2 and ATF 3 in relationship with TNM staging.  
 
 
Table 4.6: Means and standard deviation of the levels of expression of ATF 1, ATF 2 
and ATF 3 in relation to tumour stage using the TNM classification. 
 
 ATF1  ATF 2  ATF 3  
TNM 1 62.5 ± 34.3  2.9 ± 0.9  35 ± 16.3  
TNM 2 37.9 ± 27.8 p=0.58 87.5 ± 76.3 p=0.28 34 ± 14 p=0.96 
TNM 3 4.8 ± 1.5 p=0.098 21.8 ± 16 p=0.28 3.7 ± 0.8 p=0.05 
TNM 4 1.5 ± 0.76 p=0.08 411 ± 410 p=0.39 29.2 ± 18.1 p=0.75 
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Figure 4.7: ATFs transcript levels and clinical outcome  
 
Table 4.7: Means and standard deviation of the levels of expression of ATF 1,    ATF 
2 and ATF 3 in relation to clinical outcome 
(Median follow- up 120 months) 
 
 
ATF1  ATF 2  ATF 3  
Disease Free 
Survival 
49.1 ± 27.4  55.9 ± 
38.1 
 48.2 ± 
13.9 
 
Metastasis 15 ± 4.4 p=0.22 2.6 ± 1.3 p=0.17 9.1 ± 6.5 p=0.039 
Local 
Recurrence 
6.7 ± 5.1 p=0.13 6.5 ± 4.9 p=0.2 17.8 ± 8.5 p=0.15 
Death 
(Breast 
Cancer) 
2.6 ± 0.71 p=0.094 27.6 ± 
20.6 
p=0.52 5.3 ± 1.3 p=0.11 
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Figure 4.8: Comparison between patients who remained disease free and who 
had disease progression (recurrence, metastasis and mortality).  
 
Table 4.8: Means and standard deviation of the levels of expression of ATF 1, ATF 2 
and ATF 3 in relation to Disease Free Survival and Poor Prognosis 
(median follow- up 120 months) 
 ATF1  ATF 2  ATF 3  
Disease 
Free 
Survival 
49.1 ± 27.4  55.9 ± 38.1  48.2 ± 13.9  
Poor 
Prognosis 
6.2 ± 1.6 p=0.12 17.8 ± 12 p=0.34 8.5 ± 2.3 p=0.021 
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4.3.5 Immunohistochemical staining of the ATFs protein in breast cancer and 
normal mammary tissue 
The immunohistochemical staining of ATF1, ATF2 and ATF3 protein was performed in 
breast cancer and normal mammary tissue. Here, we took an extra step, by first staining 
the tissue sections with anti-ATF antibodies (Santa Cruz Biotechnology, Santa Cruz, 
California, USA) and evaluated the nucleus staining without carrying out nucleus counter 
staining. The sections were subsequently restained using hematoxyline after removing the 
cover slips, thus allowing for further matched analysis.  The staining pattern of ATF in 
tumour tissue and in normal mammary tissue was then compared. Semi –quantitative 
analysis of the 8 paired (normal and tumour tissue) samples showed that ATF1 (Table 
4.10 & Figure 4.9), ATF2 (Table 4.12 & Figure 4.13), and ATF3 (Table 4.14 & Figure 
4.17), protein staining in normal mammary and tumour tissues were showing differing 
patterns. 
4.3.6 Immunohistochemical staining of ATFs in relation to tumour prognosis 
(Nottingham prognostic Index – NPI), TNM stage and tumour grade 
The level of ATF1, ATF2 and ATF3 protein expression is higher in the grade 1 tumours 
as compared to grade 3 tumours. Of the 6 G1 samples (background =3 and tumour =3), 5 
samples each of ATF1, ATF2 and ATF3 protein staining was scored as 3+ whereas out of 
the 6 G3 samples (background =3 and tumour =3), G3 tumours were either scored 
negative (0) or weakly positive (+1) (Table 4.11, 4.13 & 4.15, Figure 4.10, 4.14 & 4.18).  
Similar trend was seen for ATF1, ATF2 and ATF3 protein  in relation to tumour 
prognosis (Nottingham prognostic Index – NPI) with the levels higher in the NPI 1 
tumours as compared to NPI 3 tumours  (Table 4.11, 4.13 & 4.15, Figure 4.11, 4.15 & 
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4.19). Interestingly the expression of ATF2 protein level is higher in the TNM 4 tumours 
as compared to TNM 1 tumours (Table 4.13 Figure 4.16). However ATF1 and ATF3 
protein expression was higher in the TNM 1 tumours as compared to TNM 4 tumours 
(Table 4.13; Figure 4.12 & 4.20) 
Table 4.9 Pathological characteristics of Breast Cancer 
 
 
 
 
Table 4.10 Immunohistochemistry staining scores of ATF1 in normal and cancer 
tissue specimen 
 
ATF1  0 +1 +2 +3 
Normal 5   2   1   0 
Cancer 0   1   3   4 
 
Table 4.11 Immunohistochemistry staining scores of ATF1 in relation to tumour 
grade, TNM stage and Nottingham Prognostic Index (NPI) 
 
 
 
 
 
 
 
 
 
GRADE TNM NPI 
GRADE 1  n =  3 
GRADE 2  n =  2 
GRADE 3  n =  3 
TNM 1  n  =  2 
TNM 2  n  =  1 
TNM 3  n  =  2 
TNM 4  n  =  3 
NPI 1  n  =  2 
NPI 2  n  =  3 
NPI 3  n  =  3 
ATF1 Background Cancer 
IHC 0   +1   +2   +3 0   +1   +2   +3 
GRADE 1  n  =  3 
GRADE 2  n  =  2 
GRADE 3  n  =  3 
0    0     1       2 
0    1     1       0 
1    2     0       0 
0    0     0      3 
0    0     0      2 
0    2     1      0 
TNM 1  n  =  2 
TNM 2  n  =  1 
TNM 3  n  =  2 
TNM 4  n  =  3 
0   0      1       1 
0   0      1       0 
1   1      0       0 
2   0      1       0 
0   0      0      2 
0   0      0      1 
0   1      1      0 
0   2      1      0 
NPI 1  n  =  2 
NPI 2  n  =  3 
NPI 3  n  =  3 
0   0      2       0 
0   1      0       2 
1   1      1       0 
0   0      0      2 
0   0      1      2 
1   2      0      0 
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Figure 4.9: Immunohistochemical staining of ATF 1 in normal mammary and 
tumour tissue 
Shown are images from non-counter stained (right panel) and counterstained sections 
(left panel). 
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Figure 4.10: ATF 1 immunostaining in breast cancer tissue 
Grade 1 tumour displayed strong immunoreactivity for ATF 1 as compared to Grade 3 
tumour which showed weak immunostaining. 
 
Figure 4.11: ATF 1 immunostaining in breast cancer tissue 
NPI 1 tumour displayed strong immunoreactivity for ATF 1 as compared to NPI 3 
tumour which showed weak immunostaining 
  
Figure 4.12: ATF 1 immunostaining in breast cancer tissue 
TNM 1 tumour displayed strong immunoreactivity for ATF 1 as compared to TNM 4 
tumour which showed weak immunostaining. 
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Table 4.12 Immunohistochemistry staining scores of ATF2 in normal and cancer 
tissue specimen 
 
 
ATF2 0 +1 +2 +3 
Normal 6   2   0   0 
Cancer 0   2   2  4 
 
 
 
Table 4.13 Immunohistochemistry staining scores of ATF2 in relation to tumour 
grade, TNM stage and Nottingham Prognostic Index (NPI) 
 
ATF2 Background Cancer 
IHC 0   +1   +2   +3 0   +1   +2   +3 
GRADE 1  n  =  3 
GRADE 2  n  =  2 
GRADE 3  n  =  3 
0   0      1      2 
1   0      1      0 
1   2      0      0 
0   0      0      3 
0   0      1      1 
2   1      0      0 
TNM 1  n  =  2 
TNM 2  n  =  1 
TNM 3  n  =  2 
TNM 4  n  =  3 
2   0      0      0 
1   0      0      0 
0   1      1      0 
0   1      1      1 
1   1      0      0 
0   1      0      0 
0   0      2      0 
0   0      1      2 
NPI 1  n  =  2 
NPI 2  n  =  3 
NPI 3  n  =  3 
0   0      0      2 
0   1      2      0 
1   2      0      0 
0   0      1      1 
0   0      1      2 
2   0      1      0 
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Figure 4.13: Immunohistochemical staining of ATF 2 in normal mammary and 
tumour tissue 
Shown are images from non-counter stained (right panel) and counterstained sections 
(left panel). 
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Figure 4.14: ATF 2 immunostaining in breast cancer tissue 
Grade 1 tumour displayed strong immunoreactivity for ATF 2 as compared to Grade 3 
tumour which showed weak immunostaining. 
  
 
Figure 4.15: ATF 2 immunostaining in breast cancer tissue 
NPI 1 tumour displayed strong immunoreactivity for ATF 2 as compared to NPI 3 
tumour which showed weak immunostaining. 
 
 
 
Figure 4.16: ATF 2 immunostaining in breast cancer tissue 
TNM 1 tumour displayed strong immunoreactivity for ATF 2 as compared to TNM 4 
tumour which showed weak immunostaining. 
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Table 4.14 Immunohistochemistry staining scores of ATF 3 in normal and cancer 
tissue specimen 
 
 
 
 
 
 
 
 
Table 4.15 Immunohistochemistry staining scores of ATF 3 in relation to tumour 
grade, TNM stage and Nottingham Prognostic Index (NPI) 
 
ATF 3 Background Cancer 
IHC 0   +1   +2    +3 0   +1   +2    +3 
GRADE 1  n  =  3 
GRADE 2  n  =  2 
GRADE 3  n  =  3 
0    0      0       3 
0    1      1       0 
2    1      0       0 
0    0      1       2 
1    0      1       0 
0    2      1       0 
TNM 1  n  =  2 
TNM 2  n  =  1 
TNM 3  n  =  2 
TNM 4  n  =  3 
0    0      1       1 
0    0      0       1 
0    2      0       0 
2    1      0       0 
0    0      0       2 
0    0      0       1 
1    1      0       0 
0    3      0       0 
NPI 1  n  =  2 
NPI 2  n  =  3 
NPI 3  n  =  3 
0    0      1       1 
2    0      1       0 
2    0      0       1 
0    0      0       2 
1    0      0       2 
0    2      0       1 
 
ATF 3 0 +1 +2 +3 
Normal 6   2  0   0 
Cancer 0   2  3   3 
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Figure 4.17: Immunohistochemical staining of ATF 3 in normal mammary and 
tumour tissue 
Shown are images from non-counter stained (right panel) and counterstained sections 
(left panel). 
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Figure 4.18: ATF 3 immunostaining in breast cancer tissue 
Grade1 tumour displayed strong immunoreactivity for ATF 3 as compared to Grade 3 
tumour which showed weak immunostaining. 
  
Figure 4.19: ATF 3 immunostaining in breast cancer tissue 
NPI 1 tumour displayed strong immunoreactivity for ATF 3 as compared to NPI 3 
tumour which showed weak immunostaining. 
  
Figure 4.20: ATF 3 immunostaining in breast cancer tissue 
TNM 1 tumour displayed strong immunoreactivity for ATF 3 as compared to TNM 4 
tumour which showed weak immunostaining. 
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4.4 Discussion 
The ATF family of transcription factors are involved in various cellular functions, 
including cell stress responses, cell survival, and cell growth. The pattern of expression of 
ATFs in benign and malignant solid tumours has showed that this protein behaves as both 
negative and positive regulatory proteins. The ATF consist of an N terminal DNA-
binding domain and a C-terminal B-ZIP (basic leucine zipper) domain which binds to 
other B-ZIP transcription factors to form homodimers and heterodimers to either activate 
or repress gene transcription and therefore have potential to regulate the transcription of 
many target genes involved in breast cancer pathology and suppression (Vinson et al., 
2002; Hai et al., 1991; Hsu et al., 1992). 
This study has demonstrated that ATF is expressed in both tumour tissues and the normal 
breast adipose tissues with higher levels in tumour tissues. ATF was shown to be 
predominantly a nucleus protein which was highly stained in breast cancer cells nucleus 
compared with normal epithelial cells.  
The current study reported for the first time that ATF is aberrantly expressed in human 
breast cancer at mRNA levels and has significant bearing to the clinical outcome of the 
patients. We assessed ATFs level in breast cancer tissue samples against the known 
prognostic factors and found significantly low levels of ATFs in patients with poor 
prognosis, metastatic disease and nodal involvement. The study has revealed a significant 
link between ATFs and mortality, in that low levels are associated with shorter disease 
free survival.  
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Similar to that of CREB1 IHC study, the number of tissues available for the 
immunohistological analyses were limited, which had refrained us from carrying out full 
statistical analysis on the semi-quantitative data. However, a future IHC study using a 
large sample cohort will be invaluable. 
This study demonstrate that the level of ATF in breast cancer patients was found to be 
elevated and is significantly raised in patients with good prognosis. Breast cancer with 
increased expression of ATF has good prognosis which could be due to anti proliferative, 
apoptotic or anti invasive property of this protein as described in various studies in other 
human cancer cell lines. We conclude that the level of ATF expression is aberrant in 
human breast cancer and may be associated with good prognosis in breast cancer patients.  
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CHAPTER 5 
 
KNOCKDOWN OF CREB 1 BY HAMMERHEAD RIBOZYME TRANSGENES INHIBIT 
CELL GROWTH AND INVASION IN BREAST CANCER CELLS 
 169 
 
5.1 Introduction 
 
Oestrogen synthesis is catalysed by the enzyme aromatase cytochrome P450 and plays an 
important role in the development of breast cancer. Hence aberrant expression of 
aromatase in breast cancer cells and surrounding stromal cells may have a significant 
influence in breast tumour pathogenesis. 
Aromatase expression upregulation in breast tumours is attributed to changes in the 
transcriptional control of aromatase expression. It has been shown that aromatase is 
expressed at a higher level both at mRNA and protein level in the breast cancer cells as 
compared to normal breast tissue (Esteban et al., 1992; Santen et al., 1994). It is known 
that in normal mammary adipose tissue aromatase is expressed through the use of 
promoter 1.4 (Mahendroo et al., 1993; Zhao et al., 1995) and in tumour tissue promoter ІІ 
(Zhou et al., 1996) and promoter I.3 (Agarwal et al., 1996; Zhou et al.,  1996) directs 
aromatase expression..  
In normal mammary tissues, Snail and Slug are expressed and prevents activators from 
binding to CREaro. This results in a suppression of promoter I.3 activity. In cancer tissue, 
human aromatase promoter usage switches to promoter I.3, activated by CRE binding 
proteins like CREB1 and also due to decrease in Snail and Slug expression. This shows 
that cAMP plays a critical role in upregulating the activity of promoters I.3 and II, leading 
to an increase in the expression of aromatase and hence oestrogen in breast cancer tissue. 
Suppression of oestrogen synthesis can be achieved by the prevention of aromatase 
expression or by the inhibition of aromatase activity in breast tumour tissues. It has been 
demonstrated that there is a switch in the aromatase promoter usage from a 
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glucocorticoid-stimulated promoter I.4 in normal tissue to cAMP-stimulated promoters 
I.3 and II in cancerous tissue.  
Although there is no study which have shown any direct link between CREB expression 
and breast cancer, CREB may be involved in tumour growth and metastasis through 
increased expression of aromatase. It has been reported that cAMP Response Element-
Binding Proteins (CREB) may act as a positive transcription regulator of aromatase and 
hence increased expression and oestrogen synthesis in breast cancer cells (Sofi et al.,  
2003). 
 171 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
Polyclonal goat anti CREB 1 IgG and monoclonal mouse anti Actin were obtained from 
Santa Cruz Biotechnology (Santa Cruz, USA). Peroxidase conjugated anti- goat and anti- 
mouse IgG for western blotting were purchased from Sigma (Poole, Dorset UK).  MDA-
MB-231 cells were grown and maintained in DMEM medium with 10% foetal calf serum 
and antibiotics. 
 
5.2.2 Construction of ribozyme transgenes targeting at CREB 1  
A hammerhead ribozyme for CREB 1 was designed based on their secondary structure 
(Figure 5.1) using Zuker’s RNA mFold programme (Zuker et al., 2003). Based on the 
cleavage site of target gene and the sequence of hammerhead ribozyme, the primers were 
designed (Table 5.1).  Hammerhead ribozyme and antisense were pre-arranged so that 
correctly oriented ribozymes were amplified. 
The respective ribozymes were synthesised using touchdown PCR. The ribozymes thus 
synthesised carried an overhang at the 3’ end of the product. The ribozyme was then 
cloned into pEF6/V5- His- TOPO plasmid vector (Invitrogen, Paisley, UK) as described 
earlier in chapter 2. Following this the vector was then transformed in E.Coli using 
electroporation. The transformed E.Coli was then incubated for 60 minutes in SOC 
medium inorder to allow the bacteria to develop resistance to the antibiotic. This was then 
plated and incubated overnight at 37ºC. Following this the clones were analysed using 
direction specific PCR to verify the presence of the ribozymes in the clone. The colony 
with correctly oriented ribozyme insert was identified using two different PCR reactions. 
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PCR reactions were carried out using T7F coupled with RBBMR primer and RBTPF 
respectively (Table 5.1). Colonies with positive T7F/RBBMR and negative T7F/ RBTPF 
were regarded as the colonies with correctly oriented ribozymes insert. These colonies 
were then selected and cultured in LB medium containing ampicillin. Following this the 
plasmid was extracted and verified using DNA electrophoresis. 
 
Table 5.1: Primers for synthesis of CREB 1 ribozymes 
 
Ribozyme 
 
Name of 
Primer 
Sequence of Primers 
 T7F 
 
5’-TAATACGACTCACTATAGGG 
 RBBMR 
 
5’-TTCGTCCTCACGGACTCATCAG 
 RBTPF 
 
5’-CTGATGAGTCCGTGAGGACGAA 
CREB RIB1F 
 
5’-CTGCAGAGTTCAGGGAAGAACATGGAGACTGATGAGTCCGTGAGGA CREB 1 
ribozyme-1 
CREB RIB1R 
 
5’-ACTAGTCCAGACCAAGATAGAACCTGTTTCGTCCTCACGGACT 
CREB RIB2F 
 
5’-CTGCAGGGATGGGCCCATGCTGATCTGCTGATGAGTCCGTGAGGA CREB 1 
ribozyme-2 
CREB RIB2R 
 
5’-ACTAGTCCCAGCCCCCTCACTTGGACCTGTTTCGTCCTCACGGACT 
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Figure 5.1: The predicted secondary structure of the CREB 1 mRNA transcript.  
      Computed using mFOLD method at: http://mfold.rna.albany.edu.Folding ID 709981. 
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5.2.3 Transfection of Breast Cancer cells and establishment of the stable 
transfectants 
Ribozyme transgene and empty plasmid vectors were transfected using the electroporator 
(Easyjet Plus, Equibio Ltd., UK) into MDA-MB-231 breast cancer cell lines. The cells 
were then immediately transferred into the 25 cm3 culture flask containing 5ml of 
prewarmed culture medium and incubated. Selection of the transfected cells was then 
carried out once the cells reached 50% -70% confluent using the selection medium 
containing the antibiotic. Following this the presence of the ribozyme and its effect on the 
expression of the respective target gene transcript was verified using RT-PCR. Verified 
transfectant were then cultured in the maintenance medium containing antibiotic (2 weeks 
for G418 and 1 week for blasticidin) to obtain sufficient cells for further experimental 
studies. 
 
5.2.4 Synthesis of complementary DNA and RT–PCR for CREB 1  
cDNA was synthesised by reverse transcription using a Dura Script RT-PCR Kit (Sigma) 
according to manufacturer’s instructions as described in chapter 2.  
The reaction conditions were as follows: 5 min at 95°C, 20 seconds at 94°C, 25 seconds 
at 56°C and 50 seconds at 72°C for 36 cycles followed by final extension phase of 7 
minutes at 72°C. The PCR products were then separated on a 0.8% agarose gel, stained 
using ethidium bromide and visualized under UV lights.   
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5.2.5 Western blot analysis of CREB 1  
Cells were lysed and after extraction protein concentrations were measured as described 
in chapter 2 using a Bio-Rad DC protein Assay Kit (Bio-Rad laboratories, UK). Briefly 
the protein samples were mixed with a sample buffer containing SDS, glycerol and a 
loading dye. Following electrophoresis proteins were blotted onto nitrocellulose 
membrane. This was followed by probing with specific primary antibody (anti- CREB 1, 
1:250) and corresponding peroxidase – conjugated secondary antibodies (1:1000). Protein 
bands were then visualised using a Supersignal TM West Dura System (Pierce 
Biotechnology, USA). 
  
5.2.6 In vitro Functional Assays 
 
5.2.6.1 In vitro cell growth assay 
 
The method used for growth assay was previously been reported by Jiang et al. 2005. 
Cells were detached from the culture flask and cell density per ml determined. Cells were 
then seeded into a 96 well plate equally (2500cells/well in 200µl of normal medium) 
(Nunclon, Fisher Scientific, UK). Three sets of plates were incubated for 1, 3 and 5 days. 
Following this the medium was removed on the day of plating and the cells were fixed in 
10% formaldehyde for 30 minutes. This was followed by staining in 0.5% (w/v) crystal 
violet for 5 minutes. The cell density was then determined by measuring the absorbance at 
a wavelength of 540nm by using spectrophotometer (Bio-Tek, Wolf Laboratories, UK). 
Cell Growth was determined as percentage increase and calculated by comparing the 
colorimetric absorbance obtained for each incubation period as follows: 
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Percentage increase = (Day 3 or Day 5 absorbance) - Day 1absorbance/ Day 1 
absorbance. 
Three independent experiments were performed with and without aromatase inhibitors. 
 
5.2.6.2 In vitro invasion assay 
 
The invasiveness of the breast cancer cells used in this study was determined using an In 
vitro Matrigel invasion assay model. The technique used during this study is described 
below. 
Twenty four well pre-chilled Cell culture inserts (Becton-Dickinson Biosciences, Oxford, 
UK) containing 8µm pores were coated in 50µg of Matrigel. 100µl (50µg) of working 
Matrigel solution was added to these cell culture inserts and was then allowed to set and 
incubated at 45ºC in a drying oven. The inserts were then placed into twenty four well 
plates and the Matrigel layers were rehydrated by incubating at room temperature for 60 
minutes using 300µl of sterile water. Following rehydration, the water was aspirated from 
each insert. Cell suspensions (15000 cells in 200µl of normal medium) were then added 
to each insert and incubated for upto 72 hours at 37ºC. The cells which had invaded into 
the Matrigel and migrated through the porous membrane to the underside of the insert 
were then fixed in 4% formaldehyde for 10 minutes at room temperature. Following this 
the cells were washed using distilled water and stained in 0.5 % crystal violet for 10 
minutes at room temperature. The cells were then air dried and the numbers of invading 
cells (random fields) were counted using a light microscope. 
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5.3 Results 
5.3.1 Effect of ribozyme transgenes on mRNA level of CREB 1 in MDA-MB-231 cells 
As shown earlier CREB 1 was highly expressed in the breast cancer cells. We transfected 
MDA-MB-231 cells with empty plasmids and the ribozyme transgenes which target 
CREB 1. The expression of CREB 1 mRNA was significantly reduced in the ribozyme 
transgene transfected cells (MDA-MB-231∆CREB 1 and MDA-MB-231∆CREB 2) as compared 
to the level of expression seen in wild type (MDA-MB-231WT) cells and MDA-MB-231 
empty plasmid (MDA-MB-231pEF/His) cells (Figure5.2). 
 
5.3.2 Effect of ribozyme transgenes on the expression of CREB 1 protein in MDA-
MB-231 cells 
Using western blot technique we found that the expression of CREB 1 protein was 
significantly reduced in the ribozyme knockdown cells as compared to the wild type 
(MDA-MB-231WT) cells and MDA-MB-231 empty plasmid (MDA-MB-231pEF/His) cells 
(Figure 5.3). 
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Figure 5.2: RT-PCR for mRNA level of CREB 1 in MDA-MB-231 cells following 
knock down using ribozyme transgene. 
 
The gene transcripts of CREB 1 was significantly reduced in the MDA-MB-231∆CREB 1 
Rib1 and MDA-MB-231∆CREB 1 Rib2 as compared to MDA-MB-231WT   and MDA-
MB-231pEF6. (Shown are representative of three separate PCR reactions).  
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Figure 5.3: Western blot analysis for protein production of CREB 1 in MDA-
MB-231 cells following knockdown using ribozyme transgene. 
 
The protein production of CREB1 is eliminated in the MDA-MB-231∆CREB 1 Rib1 
and MDA-MB-231∆CREB 1 Rib2 as compared to MDA-MB-231WT   and MDA-
MB-231pEF6. 15µg protein of each sample was used to load for SDG- PAGE. 
(Shown are representative of three separate experiments). 
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5.3.3 Effect of CREB 1 knockdown on cell growth in breast cancer  
We examined the influence on cell growth at day 3 and day 5 after knockdown of CREB 
1 in MDA-MB-231 cells with and without aromatase inhibitors. Cell growth following 
knockdown of CREB 1 was significantly reduced as compared to WT and pEF/His cells 
(Table 5.3 & 5.5; Figure 5.4 & 5.5). The cell growth of knockdown cells is further 
reduced following treatment with aromatase inhibitors (Table 5.2 & 5.4; Figure 5.4 & 
5.5). 
 
5.3.4 Effect of CREB 1 knockdown on invasiveness in breast cancer  
We further studied the effect on invasiveness following the elimination of CREB 1 in 
MDA-MB-231 cells. There was significant decreased in the invasiveness of the MDA-
MB-231∆CREB 1 Rib1 and MDA-MB-231∆CREB 1 Rib2 cells as compared to WT (MDA-MB-
231WT) and vector control (MDA-MB-231pEF6) cells (Table 5.6- 5.9; Figure 5.6- 5.10). 
The invasiveness of knockdown cells is further reduced following treatment with 
aromatase inhibitors. 
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Day 3 Control (n=6) 
Mean ± SD 
Inhibitor (n=6) 
Mean ± SD 
MDA-MB-231WT 774.49 ± 176.79 742.34 ± 411.17 
MDA-MB-231pEF/His 506.52 ± 184.26 495.51 ± 124.90 
MDA-MB-231∆CREB Rib 1 174.01 ± 63.86 164.90 ± 65.54 
MDA-MB-231∆CREB Rib 2 400.53 ± 258.44 379.81± 151.13 
 
Figure 5.4: Effect on cell growth of MDA-MB-231 cells following knockdown of 
CREB 1 using in vitro cell growth assay with and without aromatase 
inhibitor (Day 3). 
 
The error bar represents standard deviation, n=6.  This showed a significant decrease in 
the growth of the breast cancer cells following knockdown of CREB 1 as compared to the 
WT and pEF/His plasmid control cell lines (P<0.01 without aromatase inhibitor) and with 
aromatase inhibitor the data showed statistically significant decrease in the growth as 
compared to pEF/His plasmid control cell lines (P<0.01) but interestingly not with MDA-
MB-231WT   cell lines 
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Day 5 Control (n=6) 
Mean ± SD 
Inhibitor (n=6) 
Mean ± SD 
MDA-MB-231 WT 1205.00 ± 468.56 813.57 ± 415.80 
MDA-MB-231 pEF/His 996.59 ± 392.80 954.15 ± 337.30 
MDA-MB-231 ∆CREB Rib 1 327.72 ± 90.45 323.51 ± 74.46 
MDA-MB-231 ∆CREB Rib2 585.27 ± 282.74 490.43 ± 226.11 
 
Figure 5.5: Effect on cell growth of MDA-MB-231 cells following knockdown of 
CREB 1 using in vitro cell growth assay with and without aromatase 
inhibitor (Day 5). 
 
The error bar represents standard deviation, n=6.  This showed a significant decrease in 
the growth of the breast cancer cells  following knockdown of CREB 1 as compared to 
the WT and  pEF/His plasmid control cell lines (P < 0.05 with aromatase inhibitor, 
P<0.01 without aromatase inhibitor ).
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Table 5.2: Raw data for the in vitro invasion assays following knockdown of CREB 1 
in MDA231 breast cancer cell line treated with General Medium only 
 
Data for the individual repeats are depicted  along with mean, standard deviation (StDev), 
number of repeats (= n), square root of n (SQRT)  and standard error for the mean (SEM). 
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Figure 5.6: Influence on the invasiveness of MDA-MB-231 breast cancer cells 
treated with general medium, following knockdown of CREB 1 using in vitro 
invasive assay. 
 
The Error Bars represent standard deviation, n=3.  This showed a significant decrease in 
the invasiveness of the breast cancer cells  following knockdown of CREB 1 as compared 
to the WT and  pEF6 plasmid control cell lines ( * represent P ≤ 0.01 ).     
 
 184 
Table 5.3: Raw data for the in vitro invasion assays following knockdown of CREB 1 
in MDA231 breast cancer cell line treated with General Medium and Aromatase 
Inhibitor. 
Data for the individual repeats are depicted  along with mean, standard deviation (StDev), 
number of repeats (= n), square root of n (SQRT)  and standard error for the mean (SEM). 
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Figure 5.7: Influence on the invasiveness of MDA-MB-231 breast cancer cells 
treated with general medium and Aromatase Inhibitor, following knockdown of 
CREB 1 using in vitro invasive assay. 
 
The Error Bars represent standard deviation, n=3.  This showed a significant decrease in 
the invasiveness of the breast cancer cells  following knockdown of CREB 1 as compared 
to the WT and  pEF6 plasmid control cell lines ( * represent P ≤ 0.001 ).     
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Table 5.4: Raw data for the in vitro invasion assays following knockdown of CREB 1 
in MDA-MB-231 breast cancer cell line treated with HGF. 
 
Data for the individual repeats are depicted  along with mean, standard deviation (StDev), 
number of repeats (= n), square root of n (SQRT)  and standard error for the mean (SEM). 
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Figure 5.8: Influence on the invasiveness of MDA-MB-231 breast cancer cells 
treated with HGF, following knockdown of CREB 1 using in vitro invasive assay. 
 
The Error Bars represent standard deviation, n=3.  This showed a significant decrease in 
the invasiveness of the breast cancer cells  following knockdown of CREB 1 as compared 
to the WT and  pEF6 plasmid control cell lines ( * represent P ≤ 0.01 ).   
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Table: 5.5: Raw data for the in vitro invasion assays following knockdown of CREB 
1 in MDA-MB-231 breast cancer cell line treated with HGF and Aromatase 
Inhibitor. 
 
Data for the individual repeats are depicted  along with mean, standard deviation (StDev), 
number of repeats (= n), square root of n (SQRT)  and standard error for the mean (SEM). 
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Figure 5.9: Influence on the invasiveness of MDA-MB-231 breast cancer cells 
treated with HGF and Aromatase Inhibitor, following knockdown of CREB 1 
using in vitro invasive assay. 
 
The Error Bars represent standard deviation, n=3. This showed a significant decrease in 
the invasiveness of the breast cancer cells  following knockdown of CREB 1 as compared 
to the WT and  pEF6 plasmid control cell lines ( * represent P ≤ 0.001 ). 
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Figure 5.10: Effect on invasiveness following knockdown of CREB 1 with and 
without Aromatase Inhibitor. 
The Error Bar represents standard deviation, n=3. This showed a decrease in the 
invasiveness of the breast cancer cells following knockdown of CREB 1  
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5.4 Discussion 
Oestrogen synthesis is catalysed by the enzyme aromatase cytochrome P450 and is the 
primary hormonal factor that stimulates growth of hormone-dependent breast cancer. The 
expression of aromatase in breast cancer cells is up regulated compared to that of 
surrounding non cancerous tissue and can stimulate breast tumour growth in both an 
autocrine and a paracrine manner (Sun et al., 1997) It has been repeatedly demonstrated 
that aromatase is highly expressed and is directly implicated in the pathogenesis of breast 
cancer (Miller et al., 1987; Sasano et al., 1994; Lu et al., 1996;  Zhou et al., 1996; Harada 
et al., 1997).  
Till date there is no study which has shown any direct link between CREB expression and 
breast cancer. CREB may be involved in tumour growth and metastasis through increased 
expression of aromatase. Sofi et al. in 2003 reported that cAMP Response Element-
Binding Proteins (CREB) may act as a positive transcription regulator of aromatase and 
hence increased expression and oestrogen synthesis in breast cancer cells (Sofi et al.,  
2003). 
In this study we have developed the hammerhead ribozymes transgene targeting the 
CREB 1 breast cancer cells. These knocked down cells were then utilised to further 
evaluate the effects on the biological behaviours of breast cancer cells. 
In this study, we utilised the hammerhead ribozymes transgene to interfere with the 
expression of CREB 1 after transcription. The expression of CREB 1 can be successfully 
down regulated by in vitro application of hammerhead ribozymes transgene. The 
ribozymes described here are highly effective and have significantly reduced the levels of 
CREB 1 at both protein and mRNA levels. 
 189 
We examined the influence on cell growth and invasiveness after knockdown of CREB 1 
in MDA-MB-231 cells with and without aromatase inhibitors. Loss of CREB 1 is 
associated with decreased growth and invasion potential in breast cancer cells.  These 
demonstrated the potential positive regulatory effect of CREB 1 on cellular growth in 
breast cancer. There was no difference on cell growth and invasiveness between  MDA-
MB-231 cells treated with aromatase inhibitors when compared with cells without 
aromatase inhibitor. Limited by time, the present study was unable to further examine the 
impact of CREB1 manipulation on the expression of aromatase and the cells response to 
aromatase inhibitors especially in oestrogen positive cell lines, which will be an exciting 
research lead to pursue. It is hope that this will form a future research project. 
This study showed that the growth was significantly reduced following knockdown of 
CREB 1 and may have independent role in the metastatic potential of breast cancer and 
hence have the therapeutic potential in both oestrogen positive and negative tumours. 
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CHAPTER 6 
 
DISCUSSION 
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6.1 Discussion 
 
Transcription factors are gene regulatory proteins and play a vital role in the process of 
cancer cell proliferation. Transcription factors are involved in various organismal 
processes like cellular differentiation, DNA replication, cell growth and apoptosis. They 
represent prime targets for disruption in tumourigenesis, attribute to their inherent 
modular structure encoding various activating or repressing cellular functions. Breast 
cancer results from acquired or inherited gene defects leading to genomic instability and 
hence abnormal expression of transcriptional factors which in turn leads to increased 
proliferation of transformed mammary cells (Jackson et al., 1998; Loeb et al., 1998).  
Aberrant transcriptional activity and expression of CREB family of proteins in cancer 
cells and clinical tumours has long been recognised. These molecules have been 
extensively studied in relation to stress response, memory and in solid tumours, both 
benign and malignant. CREB proteins behave as both negative and positive regulatory 
proteins in different solid tumours. Chen et al. reported that in cancer tissue increased 
levels of positive regulatory proteins like ERRalpha1 and CREB1 is present as compared 
to negative regulatory proteins like EAR-2, COUP-TFI, Snail and Slug proteins (Chen et 
al., 2005). Coxon et al. have shown a link between an oncogenic chromosomal 
translocation and CREB activation in malignant salivary gland tumours (Coxon et al., 
2005). CREB has an antimitogenic role in solid tumours like glioblastoma proliferation 
and decreased expression is seen in thyroid carcinoma. Beside this ATFs has been 
implicated in various other malignant processes including HBV mediated 
hepatocarcinogenesis and melanoma (Ishiguro T et al., 2000). 
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Studies on any direct link between the expression of these proteins and breast cancer are 
yet to come. We therefore conducted this study to investigate the expression pattern of 
CREB family of proteins in cohort of breast cancer and normal background tissue in 
relation to tumour histopathological grade, stage and nodal status. We also correlate the 
level of expression with the prognosis and clinical outcome of the patients. 
In this study, we examined the expression of these transcription factors and aromatase in 
breast cancer cell lines using RT-PCR. Interestingly we found increased expression of 
CREB family of proteins in both MDA-MB-231 and MCF 7 cell lines with minimal 
aromatase activity in MDA-MB-231 cell line. These results provided us with a basic 
assessment of the function of these proteins and helped to choose a suitable cell line for 
further biological functional study. We further examined the expression of these proteins 
in Breast specimen using immunohistochemical staining. We found that CREB is 
expressed in both tumour tissues and the normal breast adipose tissues with higher levels 
in tumour tissues. CREB was shown to be predominantly a nucleus protein which was 
highly stained in breast cancer cells nucleus compared with normal epithelial cells.  
The current study reported for the first time that CREB 1, ATF 1, ATF 2 and ATF 3 
proteins are aberrantly expressed in human breast cancer at both protein and mRNA 
levels and has significant bearing to the clinical outcome of the patients. We assessed 
CREB-1 level in breast cancer tissue samples against the known prognostic factors and 
found significantly raised levels of CREB1 in patients with poor prognosis, metastatic 
disease and nodal involvement. The study has revealed a significant link between CREB 
and mortality, in that high levels are associated with shorter disease free survival.  
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We further assessed the ATF’s level in breast cancer tissue samples and demonstrated that 
the level of ATF in breast cancer patients was found to be elevated and is significantly 
raised in patients with good prognosis as contrast to the expression of CREB1. Breast 
cancer with increased expression of ATF has good prognosis which could be due to anti 
proliferate, apoptotic or anti invasive property of this protein as described in various 
studies in other human cancer cell lines (Ishiguro et al.,  2000 ; Allen and Jennings et al., 
2001). Oestrogen is a steroidal hormone that stimulates growth of hormone-dependent 
breast cancer. Oestrogen synthesis from C19 steroids is catalysed by the enzyme aromatase 
cytochrome P450 and hence aberrant expression of aromatase in breast cancer cells and 
surrounding stromal cells may have a significant influence in breast cancer pathogenesis. 
Aromatase is expressed at a higher level at mRNA and protein level in the breast cancer 
cells as compared to normal breast tissue (Esteban et al., 1992). It has been reported 
previously that there is increase aromatase expression due to increase in CREB induced 
promoter II and promoter I.3 activity in tumour bearing breast adipose tissue via CRE1 
and CRE2 (Sofi et al., 2003). In normal mammary tissue, the function of promoters I.3 
and II is suppressed through the binding of EAR-2, COUP-TFI, and RARγ to S1 (Yang et 
al., 1998; Yang et al., 2002), and Snail/Slug proteins to CREaro (Chen et al., 2002). In 
cancer tissue, the expression levels of EAR-2, COUP-TF1, EARγ, Snail, and Slug 
decreases, and aromatase expression is then up-regulated through the binding of ERRα to 
S1 and the binding of CREB1 to CREaro ( Yang et al., 1998 ; Yang et al., 2002). Hence 
cAMP plays a critical role in upregulating the activity of promoters I.3 and II, leading to 
an increase of the expression of aromatase/oestrogen synthesis in breast cancer cells. 
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The role of CREB in relation to aromatase expression is still unclear. Over-expression of 
aromatase in adipose tissue surrounding breast tumour could arise through increase in 
both CREB expression and CREB transcriptional activity and that CREB may be 
involved in tumour growth and metastasis through increased expression of aromatase 
However, despite the extensive work on aromatase and its association with breast cancer, 
little information is available on the potential role of CREB in human breast cancer.  
Following the examination of the expression of CREB in breast cancer cells, we 
successfully knocked down CREB 1in breast cancer cell line using ribozyme transgene. 
This is the first time a ribozyme transgene system has been used to reduce the expression 
of CREB 1 in breast cancer cell line. Down – regulation of the expression of CREB 1 in 
the MDA -231 cells following knock down by ribozyme transgene resulted in decrease 
cellular invasiveness and reduces the cellular growth. We further treated the knockdown 
cells with aromatase inhibitor and HGF. The result demonstrated that aromatase inhibitor 
treated cells showed further reduction in both cellular invasion and growth but was not 
significant as compared to untreated CREB 1 knock down cells.  The results in this work 
showed that there is a potential direct link between CREB 1 and breast cancer progression 
as reported previously in various cancer cell lines like ovarian cancer cells and breast 
cancer cells using CRE- transcription factor decoy oligonucleotides (Lee et al., 2000). 
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Figure 6.1: Diagrammatic presentation of CREB 1, ATF 1, ATF 2 and ATF 3 
showing the expression pattern in breast cancer tissue.   
CREB 1 is associated with poor prognostic tumours and is implicated in increase 
invasion and growth of breast cancer cells. ATF’S are associated with good 
prognostic tumours with decreased expression in poor prognostic breast tumours. 
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6.2 Prospects of future study 
In this study, we have demonstrated the positive regulatory effect of CREB 1 in breast 
cancer cells. As explained earlier the possible mechanism whereby CREB 1 elicit changes 
in the biological function of breast cancer cells still remains unclear and will require 
further study. Furthermore the potential role of other members of this family including 
ATF 1, ATF 2 and ATF 3 in breast cancer needs further input.  
Limited by time, we were unable to examine the impact of CREB1 manipulation on the 
expression of aromatase and the CREB-1 knockdown cells response to aromatase 
inhibitors especially in oestrogen positive cell line, which will be an exciting research 
lead to pursue.  
Further studies needs to be done whether increased expression of CREB 1 leads to 
aberrant aromatase expression and whether there is simultaneous decrease in the 
expression of the negative regulatory proteins like Snail and Slug proteins in breast cancer 
tissue. 
Aromatase inhibitors have been extensively used in the treatment of advanced breast 
cancer, both in the adjuvant and in the neo adjuvant setting and are shown to be superior 
to the ER antagonist. Inhibition of CREB activity could inhibit aromatase expression and 
hence decrease oestrogen production in breast tissue. Henceforth over-expression of 
CREB, together with aromatase in breast cancer tissue at both transcriptional and 
translational levels may provide a link between CREB pathways and breast 
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tumourigenesis and in future may help in the design of anti CREB therapy based on 
inhibiting aromatase expression as therapeutic strategies in breast cancer patients.  
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